Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
>>> Amgen Delves Further Into Immune Therapies With Horizon Deal
Bloomberg
Dec 2022
by Dinesh Nair, Katie Roof and Angelica Peebles
https://www.msn.com/en-us/money/companies/amgen-to-buy-horizon-therapeutics-in-27-8-billion-deal/ar-AA15boCe?cvid=783ceba35ad741849a60e74acb7763f0
(Bloomberg) -- Amgen Inc. agreed to buy Horizon Therapeutics Plc for about $27.8 billion in its biggest-ever acquisition, deepening its commitment to treatments for autoimmune, inflammatory and rare diseases.
Amgen will pay $116.50 a share in cash, the companies said in a statement Monday, for a premium of about 48% since Horizon Therapeutics disclosed on Nov. 29 that it was in early talks with three suitors. The announcement confirms an earlier report by Bloomberg News.
Horizon shares gained as much as 15% to $112 as of 1 p.m., their highest intraday level since April. Amgen’s fell 1.5%.
Horizon’s therapeutic focus overlaps with that of Amgen, the maker of the Enbrel treatment for autoimmune ailments like psoriasis and ankylosing spondylitis. Such therapies are often tested and used in a wide variety of indications after inititally reaching the market, which can add to sales. Horizon gets almost half its $3.6 billion in annual sales from Tepezza, a treatment for a painful autoimmune condition called thyroid eye disease. In October, Amgen acquired another drug company with a similar immune focus, ChemoCentryx Inc.
Emerging from the exhausting focus on Covid-19, big drugmakers are resuming their search for innovative therapies, especially for those that treat rare diseases and cancer. The deal for Horizon is the biggest in pharma since AstraZeneca Plc bought Alexion Pharmaceuticals for $39 billion in 2020. Horizon is developing drugs for conditions including lupus, alopecia, arthritis and kidney transplant rejection.
Amgen in particular is contending with the threat of diminished revenue as some of its biggest products face the loss of patent protection in the coming years.
“That Amgen is looking for larger deals is not surprising,” given expected erosion of its base business, Wolfe Research analyst Tim Anderson said in a note. “Most often it is companies with future holes to fill that do bigger deals.”
Horizon Therapeutics' acquisition makes a "good strategic and financial sense" for Amgen, says Mizuho's Salim Syed
The deal has the potential to provide a sales boost to Amgen, executives said on a call with investors.
“We’ve admired Horizon’s success for some time and we’ve studied their business closely through time as well,” Amgen Chief Executive Officer Robert Bradway said. “And when presented with this opportunity, we were prepared to move quickly.”
Murdo Gordon, Amgen’s executive vice president for global commercial operations, declined to project potential revenue, citing securities rules in Ireland, where Horizon is based. He said that rapid growth of several of Horizon’s drugs in the US may foreshadow similarly trends in other countries.
“As we secure reimbursement and launch the products in other countries, you can imagine that there’s a lot more growth to generate,” he said.
Sanofi SA dropped out of the running for Horizon Sunday, saying the price had gotten too high, following in the footsteps of a Johnson & Johnson unit earlier this month. The French drugmaker said the “transaction price expectations do not meet our value creation criteria.”
Outperformed Rivals
Thousand Oaks, California-based Amgen has far outperformed those rivals this year, with its stock rising 24% through Friday to a market value of about $149 billion. Amgen last month reported revenue and profit that beat analyst estimates as 11 drugs had record quarterly sales and the company kept operating expenses in check.
Amgen said the purchase of Horizon is expected to increase earnings per share, on a non-GAAP basis, starting in 2024. It anticipates $500 million in annual pre-tax cost savings by the end of the third fiscal year after completion.
Amgen will fund the purchase with a $28.5 billion bridge credit facility from Citigroup Inc. and Bank of America Corp. This is the second time this year the banks have teamed up to advise and fund a large deal, following their work on Philip Morris International Inc.’s purchase of Swedish Match. Amgen had almost $11.5 billion in cash and equivalents at the end of the third quarter.
Horizon, which is traded on the Nasdaq exchange and headquartered in Dublin, has US operations in Deerfield, Illinois, and Rockville, Maryland.
<<<
---
>>> A $40 billion Merger Monday shows M&A appetite increasing after brutal 2022
Yahoo Finance
by Alexandra Semenova
December 12, 2022
https://finance.yahoo.com/news/a-40-billion-merger-monday-shows-ma-appetite-increasing-after-brutal-2022-180716456.html
As investors wrap up one of the most challenging years on record, signs of life in the M&A market suggest risk appetite might be increasing as we approach the new year.
U.S. investors were met with at least $40 billion worth of deals ahead of the open Monday, led by Amgen’s acquisition of Horizon Therapeutics, Microsoft’s new stake in the London Stock Exchange Group, Coupa Software’s sale to Thoma Bravo, and a move by Weber to go private.
This deluge of deals in one of the year's final weeks comes during a challenging time for M&A as volatile markets, tighter financial conditions, and other macroeconomic headwinds choke off deal financing and cause dealmakers to postpone transactions.
In Q3, global M&A activity saw its worst quarter since the start of the COVID pandemic in 2020.
Third-quarter deal value stood at $443 B, half of the sum of transactions in the second quarter, and a decline of 58% from the same period last year, according to data from S&P Global Market Intelligence.
Amgen (AMGN) on Monday announced plans to buy biopharmaceutical company Horizon Therapeutics in a transaction totaling $27.8 billion. The purchase is part of a bid by Amgen to expand its portfolio of drugs for rare diseases.
Elsewhere in a rush of activity that kicked off the week, Coupa Software (COUP) entered an agreement to sell itself to private equity giant Thoma Bravo in an all-cash transaction valued around $6.2 billion. Coupa will become a privately-held company after closure of the deal.
Gillmaker Weber (WEBR) also locked in a take-private deal with BDT Capital Partners, which is expected to shell out $3.7 billion for the purchase.
Meanwhile, Microsoft (MSFT) is set to spend $2 billion for a 4% stake in the London Stock Exchange Group. The tech giant said Monday the 10-year strategic partnership is expected to generate $5 billion in revenue for Microsoft as it marks its largest foray into the financial services industry, while LSEG’s revenue stands to grow over time from a migration to Microsoft’s products.
While bankers navigated a sizable drop-off in dealmaking this year following a boom in 2021, the M&A landscape is poised to improve next year.
A washout in public markets — particularly in the technology sector — has sent valuations tumbling, offering vast potential for consolidation in the space. Private equity firms, despite more cautions transactions this year, are also strapped with capital to deploy.
Just days before Monday's purchase of Coupa, Thoma Bravo touted the completion of fundraising for its largest technology buyout fund ever, with $32.4 billion in capital commitments.
"While the higher cost of taking on debt does make acquisitions more challenging, remember that private equity firms have an unprecedented amount of dry powder in their reserves," Louis Lehot, Brandee L. Diamond, and Eric Chow of corporate law firm Foley & Lardner said in a recent blog.
The authors noted firms may use different capital structures to work around higher rates. "The combination of these factors has the potential to bolster activity next year."
<<<
---
$BOMO Fresh Merger/Making Revenues/Big News for Bowmo Inc. ????? Zidar OnTop & Hot
Penny Stocks ~$BOMO
Click here:
Apple / Disney - >>> Why Bob Iger’s Ultimate Power Move May Be Selling Disney to Apple
The Wrap
Joe Bel Bruno
November 22, 2022
https://www.yahoo.com/entertainment/why-bob-iger-ultimate-power-193000597.html
Now that Disney CEO Bob Iger has regained the keys to the Magic Kingdom — less than three years after his chosen successor, Bob Chapek, took over — insiders suspect they know how the beloved executive will find a new way to go out on top during his final two-year stint.
“He’s going to sell the company,” one Disney insider who has worked for Iger predicted. “This is the pinnacle deal for the ultimate dealmaker.”
Landing a deal with Apple (or some other megabuyer) would also cement Iger’s legacy. “I think he’d welcome it — he’d be the last CEO of Disney,” a former top Disney executive told TheWrap, noting that the two companies have “similar brand identities” and could benefit from a merger.
Acquisitions are in Iger’s DNA. Under Iger’s leadership, Disney went on a nearly $100 billion shopping spree to buy animation giant Pixar in 2006, superhero juggernaut Marvel in 2009, “Star Wars”-powered Lucasfilm in 2012 and Rupert Murdoch’s 21st Century Fox in 2019. But there was one acquisition he’s publicly lamented as a transformational deal that got away — a combination with the tech powerhouse Apple.
In Iger’s 2019 autobiography “The Ride of a Lifetime,” the executive wrote chapters about his friendship with Steve Jobs. He and his wife, Willow Bay, were close friends with Steve and Laurene Powell Jobs, even spending holidays together and vacationing in Hawaii. He even writes about standing in front of Steve Jobs’ grave when the tech visionary’s wife uttered: “I asked him if we could trust you. And Steve said, ‘I love that guy.’ ”
Iger responds: “The feeling was mutual.”
Yes, there are caveats — chief among them that Jobs died in 2011. And Disney is a big pill to swallow, with a $180 billion market valuation that would easily soar to a $200 billion premium if the studio were to be acquired.
A deal of that size is likely to draw stiff antitrust resistance at a moment when regulators have stepped up efforts to block other recently proposed media megadeals. Paramount Global this week scrapped the $2 billion sale of its Simon & Schuster division to book publishing giant Penguin Random House after a federal judge blocked the deal, while European regulators have launched a probe of Microsoft’s $69 billion offer to purchase gaming giant Activision Blizzard.
Apple CEO Tim Cook, known to be a safe player with relatively few acquisitions under his leadership, might have given Wall Street a big hint in April. During a call with investors, Cook said he would not rule out acquiring a large company, and that the main drive was to secure strong intellectual property and big names.
Hello, Disney?
Disney CEO Bob Iger Lines Up Potential $27 Million Annual Payday
“We are always looking at companies to buy, we acquire a lot of smaller companies and we’ll continue to do that for IP and to incorporate talent,” Cook said. “We don’t discount something larger if the opportunity presents itself. I’m not going to go through my list with you on this call, but we’re always looking.”
Apple, which has been tinkering with a grab in the streaming space with hits like “Ted Lasso,” certainly has the financial firepower to pull off an acquisition of this size. Even as borrowing costs get more expensive with rising interest rates, the Cupertino-based company is sitting on top of a $48.3 billion cash stockpile. Fleshing that out to both cash and investments, the total surges to about $200 billion. That’s 7.4% of all the mad money held by every member of the broad Standard & Poor’s 500 index.
Not to mention that Apple shares have skyrocketed since Iger and Jobs first did business together. Disney bought the Jobs-run Pixar in 2006 for $7.4 billion, which put the animation studio’s CEO on the entertainment company’s 10-member board. On the day the deal was announced, Apple was trading at about $3 a share and Disney at $25.
Apple is now trading at $150, up 238% in the past five years. Disney, at $96, is down 6% during that same period.
A rep for Disney had no comment; an Apple rep did not respond to requests for comment.
<<<
---
>>> AgroFresh Solutions rallies on buyout deal with Paine Schwartz Partners
MarketWatch
Nov. 22, 2022
By Steve Gelsi
https://www.marketwatch.com/story/agrofresh-solutions-rallies-on-buyout-deal-with-paine-schwartz-partners-2022-11-22?siteid=yhoof2
AgroFresh Solutions Inc. AGFS, +5.56% rose 4.7% in premarket trades Tuesday after the company confirmed a go-private buyout deal with sustainable food chain investing firm Paine Schwartz Partners. Philadelphia-based AgroFresh said it agreed to be acquired for $3.00 per share. The stock closed at $2.79 a share on Monday, with a market capitalization of $150 million. AgroFresh CEO Clint Lewis said the deal will "provide enhanced flexibility for AgroFresh to build on its strong foundation and advance its mission of preventing food waste and conserving the planet's resources for years to come."
<<<
---
>>> Dumping Trump Is Just the Start of Rupert Murdoch’s Ugly New Era
Daily Beast
by Clive Irving
November 16, 2022
https://news.yahoo.com/dumping-trump-just-start-rupert-095408268.html
Rupert Murdoch is not just dumping Donald Trump. He wants back his role as the world’s most feared media mogul.
At the age of 91, Murdoch has cast off what he felt were the shackles of a constraining marriage and is in the process of regaining total control of his global media empire, as well as reasserting his political influence in America.
This won’t be easy. He has to persuade the stockholders in the two halves of his empire, Fox Corp and News Corp, that they should be merged into one, with him at the top—nearly a decade after they were forced to split up when his British tabloids, part of News Corp, were exposed to the huge legal costs of a phone-hacking scandal.
His decision to merge the companies has angered stockholders in both—for different reasons. Many investors in News Corp, which houses Murdoch’s legacy newspaper businesses, don’t want to be associated with Fox News—as one told the Financial Times, “Fox News is kind of toxic and should be ringfenced.” On the other side, Fox investors fear that their company, which gushes profits, would lose value by being in the same stable as the newspapers, in a struggling sector with far larger costs and that generates far less money.
In short, it is hard to find anyone who thinks the merger makes any sense in business terms. Nor, as some have suggested, is it a necessary step to simplify the Murdoch dynastic succession when the mogul does decide to retire—or after his death.
“This is a move to centralize things around him in the U.S.,” explains Claire Enders of Enders Analysis, one of the best-informed trackers of the Murdoch empire. “He wants to be back in the thick of things, it’s much more attractive to him than any option elsewhere. He is entitled to exercise leading shareholder status, keeping a grip on his media assets.” Nonetheless, in a guidance for investors by Enders Analysis, they warned that the terms of the merger were weighted against the interests of Fox shareholders and cautioned that a similar merger of Viacom and CBS left the resulting Paramount Global worth $13 billion less than if the two had remained separate.
The first and most intimate casualty of Operation Rupert Redux is his fourth wife, Jerry Hall. When they married in 2016 (apparently a coupling encouraged by Murdoch’s top News Corp executive in the U.K., Rebekah Brooks) it seemed like a shot of late-life Viagra with Murdoch declaring that he was “the luckiest AND happiest man in the world.” Nobody outside the family really knows what Hall meant when, announcing the split early this summer, she cited the tired legal sophistry “irreconcilable differences.”
There were claims that, in the eyes of the Murdoch family, she became an over-protective gatekeeper during the COVID pandemic while they were living in England. (As Fox News was touting quack remedies, debunking vaccination, and demonizing Anthony Fauci, Murdoch was at the head of the queue at Henley, near London, for his first shot from the National Health Service.) A more likely annoyance is that Murdoch felt his wife was designing around them an opulent version of assisted living involving English country mansions and the tweedy Cotswold crowd while, all the time, he was yearning, yearning, to get back to an entirely different life, the only one that he ever really loved, at the helm of his empire in New York, rolling up his sleeves and making political mischief—being the old Rupert Murdoch who founded his business on his salty London tabloid, The Sun.
So, come the middle of August, the lawyers for each side settled the terms of the divorce (she got the English country estate among other treasure) and Murdoch was heading west. Last week, showing his shark-like instinct for blood in the water, he was in New York when the Trump train crashed in the midterms and his Manhattan tabloid, the New York Post, produced a classic Sun-style front page headlined “Trumpty Dumpty…Don (who couldn’t build a wall)—can all the GOP’s men put the party together again?” Another front page, alerting us to his new favorite, hailed Florida governor Ron DeSantis as “DeFuture.” At the same time, Murdoch’s far more dignified organ, the Wall Street Journal, editorialized: “Trump has led the Republicans into one political fiasco after another.”
Of course, that’s just the fun bit, part of the day job. The serious business is getting the merger done. Enders says, “The shareholders know they will get a better offer. This is a six-month problem, but they will be enticed.”
That involves setting a price at which the stigma of accepting coin from the pungent profits of Fox News becomes acceptable. After all, talking about “ringfencing” is, in ethical terms, merely a fig leaf that cannot shield the grotesque instrument beneath.
In any event, the News Corp problem, that it will undermine the market value of the merger, is more of an issue for Wall Street. Peter Kreisky, an authority on the digitization of the media and long-time follower of the Murdoch businesses, says, “Investors know that the print news business is in long-term decline, dependent on successful adaptation to digital. News Corp is struggling with that. In comparison, Fox Corp is a thriving $14 billion a year money machine, and Fox News is the beating heart of Fox’s programming appeal. The expectation must now be that Fox News will be reinvigorated by internecine warfare within the Republican Party following the disastrous performance of Trump’s candidates.”
The Trump presidency took Fox News to the heights of its fortunes. The White House and Fox News were joined at the hip. Murdoch had weekly talks with Trump and Fox News anchors, notably Sean Hannity, served as Trump whisperers. That’s why Murdoch’s dumping on Trump now seems so ruthless. “The impression was,” says Enders, “that they were working together against political trends that they didn’t like.”
With Murdoch now looking at 2024 and seeing no future for Trump it will be interesting to see how long it takes Fox News to complete the same pivot. Ten days before the midterms, Tucker Carlson called Biden “a mentally defective president who can barely speak.” Who is the dumb one now?
Murdoch also has a direct commercial interest in stoking up the noise of extreme partisan politics: Fox News, as the single most watched news channel in the country, is the greatest beneficiary of the ever-increasing torrent of political attack ads on television.
All of this puts the spotlight on Murdoch’s eldest son, Lachlan, who has been nominally in charge of Fox News while his father was in his English limbo. Of the older Murdoch children, Lachlan, says Enders, is the one with political views most similar to his father. But the merger is a reminder of how different the internal family dynamics were when Murdoch was last the ruling power over all the businesses, and particularly of the role of his second son, James.
James was, points out Enders, for many years in charge of the corporate deal making, and was instrumental in putting together the deal that eventually made the Murdoch family fortune, the sale in 2018 of the Fox Hollywood and TV entertainment assets to Disney for a staggering $71.3 billion.
“Before the sale to Disney” says Enders, “the children had no money of their own. They relied on Rupert for their lifestyle.” (Elisabeth, Murdoch’s second daughter, became independently wealthy in 2016 when she sold her TV production company, Shine, to her father for $214 million). James had expected to become chief executive of Disney when the sale was concluded but, says Enders, “Rupert pulled the rug out from under him.”
That goes to the heart of the bad blood in the dynasty. At the beginning of his career in the empire, it was James, not Lachlan, who seemed the golden boy. As well as his business acumen he parroted his father’s prejudices, against the BBC in particular and public broadcasting in general. To Rupert Murdoch, the BBC assembled many demons: liberal bias, publicly subsidized editorial profligacy, the worst of British elitism.
The Last Act of Rupert Murdoch’s Dynasty May Be Its Ugliest
But that blind loyalty began to unravel after James was appointed to clear up the mess left by the tabloid hacking scandal, when his father reluctantly stepped down from running the papers. This involved closing the News of the World, where the hacking was deeply embedded in the newsroom as a generator of endless scoops. It was a tough move to make: the News of the World was the first paper that Murdoch bought in London in 1969 as the basis of his new global ambitions. But the legal consequences of the hacking—years of litigation over compensation payments to the victims—made it imperative to split News Corp from Fox to contain the damage. Even then, says Enders, “Rupert resisted the split and it was only when he was out the door and James was in charge that it happened at all.”
Until then, James had never glimpsed the brutal competitive culture of a tabloid newsroom as nurtured by his father. “He was personally and professionally suddenly in the frame of a journalistic culture that he found abhorrent,” says Enders. And that was what led to a change of view about the integrity of television news when James was put in charge of a tough fight with British regulators to get approval for the Murdochs to take full control of Sky News, a satellite broadcaster. Regulators and politicians feared that Sky News would become a clone of Fox News and a bullhorn for Murdoch. James clinched the deal by pledging full financial and editorial independence for the network for 10 years. It was, says Enders, “a brilliant suggestion that strengthened the plurality of British television news. Sky News has won myriad industry awards.” In 2018, Sky News was sold to the U.S. media conglomerate Comcast for $39 billion, and the pledge of its editorial independence was renewed.
Enders says that during his time in the company James “stewarded a tenfold increase in the family’s wealth.” How different it is now. Enders believes that the succession is settled, with Lachlan secure as the heir. “I doubt James has any contact at all with his father, except remotely, because they’ve had some well known falling-outs. The motivation for a coup isn’t there. The elder children are all extremely wealthy and Elisabeth and James are value creators in their own right.”
Fox News Is Fully Tucker TV Now That Chris Wallace Is Gone
In London, there is a significant change in editorial priorities—and culture. The tabloids no longer decide the fortunes of News Corp. For a long while their profits helped to support the upmarket papers, The Times and Sunday Times. In 2010 the two broadsheets made a loss of 42 million pounds; in 2021 they made a profit of 45 million pounds, largely due to their digital editions, while The Sun made a loss of 44 million pounds. It is likely that the broadsheets will become even more profitable when, as is rumored to be imminent, the two are combined into a seven-day brand in print and digital.
Both Enders and Kreisky see The Sun as a significant drag on News Corp profits. Although British tabloids have long provided the template for successful international websites—Mail Online is one of the top rated sites in the U.S. and the world—The Sun has only recently gone digital in the U.S., where, says Kreisky, its growth has stalled “for lack of constantly compelling content. It needs a ‘content doctor’ to inject a riveting must-read tabloid sensibility. There is also an opportunity for cross-promotion of The Sun and Fox News. But when it comes to digital, Murdoch himself has never made the transition editorially or as a strategist from print.”
The jewel of News Corp, says Kreisky, is not in London but New York—Dow Jones, publisher of the Wall Street Journal. “In the most recent quarter it posted a 26 percent rise in revenue to $565 million and had 3.1 million digital-only subscribers, making it one of a handful of traditional print publications to have successfully become a top digital property.”
As a media gold mine, Fox Corp is a lot more more than Fox News. It has enormous reach in the U.S., delivering news, sports and entertainment to 208 local stations, including 18 that it owns and operates itself. It also feeds news and sports to 75 million subscribers through cable and broadband operators like Comcast, Verizon, and AT&T. Were it not for the odium of Fox News the corporation would be seen as a model of nimble and far-sighted media management. But Rupert Murdoch’s return to the heart of his business and his complicity, through Fox News, in the debasement of American politics by Donald Trump can’t be wiped from the record simply by dumping Trump now.
President Biden called Murdoch “the most dangerous man in the world.” This was absurd hyperbole—there are several more obviously qualified candidates for that title. But Murdoch’s baleful influence on American politics and democracy through Fox News will be his most lasting legacy, and it’s obvious that he’s not done yet—as Enders put it, “Rupert Murdoch does not believe that his time is up.”
<<<
---
>>> Primo Water (PRMW) Unit Acquires Crystal Spring Water Company
Zacks Equity Research
October 14, 2022
https://finance.yahoo.com/news/primo-water-prmw-unit-acquires-151803695.html
Primo Water Corporation PRMW has announced that its subsidiary, Primo Water North America ("PWNA"), has acquired substantially all assets of Crystal Spring Water Company, a bottled water company based in Rhode Island. This acquisition will add 2,500 customers to PWNA’s existing customer base and further expand its operations in the Northeast region.
Crystal Spring Water Company provides high-quality spring water solutions and delivers superior customer service, which is in sync with Primo Water’s objective to provide high-quality water services and solutions to its customers.
Primo Water has been expanding internationally through strategic acquisitions. Recently, its subsidiary Primo Water Europe acquired Eureau Sources and Defeaus, two France-based companies specializing in the marketing and packaging of spring water.
Acquisition Essential for Fragmented Industry
Per the Environmental Protection Agency, at present, more than 51,000 community water systems and 16,000 community wastewater systems in the United States are providing water solutions to customers. Due to a large number of small operators in the industry and a lack of adequate funds, at times, essential upgrades and repairs of infrastructure get delayed.
The acquisition of small units by larger utilities ensures necessary investments for the upgrade of infrastructure and the continuation of high-quality services for customers.
Water utilities like American Water Works AWK, SJW Group SJW and Essential Utilities WTRG, among others in the water utility space, are expanding operations through systematic acquisitions.
American Water Works continues to focus on the acquisition of utilities that provide services to 5,000-50,000 customers. Through nine buyouts, the company added 51,000 customers to its existing customer base. Its pending acquisitions (as of Jun 30, 2022), when completed, will add another 29,200 customers to its base. Its long-term (three to five year) earnings growth is currently pegged at 8.08%.
The Zacks Consensus Estimate for American Water Works 's 2022 and 2023 earnings implies year-over-year growth of 4.5% and 8.8%, respectively. It currently has a Zacks Rank #3 (Hold).
SJW Group completed more than 25 acquisitions in the 2010-2021 time frame and expanded operations. In January 2022, it closed the acquisition of Texas Country Water in Comal, TX. The deal added more than 1,900 water and wastewater customers to the existing customer base. This has been the fourth Texas acquisition by SJW Group in the past 12 months. In the next five years, the company plans to invest $1.5 billion to further strengthen its infrastructure.
The Zacks Consensus Estimate for SJW Group's 2022 and 2023 earnings implies year-over-year growth of 15.3% and 9%, respectively. It currently has a Zacks Rank #3.
In the six years ended Dec 31, 2021, Essential Utilities expanded utility operations by completing many water and wastewater acquisitions, which, in turn, added 94,000 customers. In the first quarter of 2022, the company completed one buyout, which added 11,000 customers. It plans to invest $3 billion from 2022 through 2024 to fortify operations and efficiently serve its expanding customer base.
Essential Utilities’ long-term earnings growth is currently pegged at 6.2%. The Zacks Consensus Estimate for WTRG's 2022 and 2023 earnings implies year-over-year growth of 6.6% and 6.7%, respectively. It currently has a Zacks Rank #2 (Buy).
Price Performance
Shares of PRMW have gained 5.5% in the past three months against the industry’s 6.7% decline.
<<<
---
>>> Westinghouse to be sold in $7.9-bln deal as interest in nuclear power grows
Reuters
Oct 12, 2022
By Kannaki Deka and Arunima Kumar
https://www.reuters.com/markets/deals/cameco-corp-brookfield-renewable-partners-buy-westinghouse-79-bln-deal-2022-10-11/
Oct 11 (Reuters) - Cameco Corp (CCO.TO) and Brookfield Renewable Partners said on Tuesday they would acquire nuclear power plant equipment maker Westinghouse Electric in a $7.9-billion deal including debt, amid renewed interest in nuclear energy.
The deal for one of the most storied names in the American power industry at an equity value of $4.5 billion comes at a time when nuclear power is seeing an uptick in interest amid an energy crisis in Europe and soaring crude oil and natural gas prices.
Nuclear power is also key for countries to meet global net-zero carbon emission goals and could be on the cusp of a boom seen after the 1970s oil crisis.
"We’re witnessing some of the best market fundamentals we’ve ever seen in the nuclear energy sector," Uranium fuel supplier Cameco's chief executive, Tim Gitzel, said.
Cameco will own 49% of Westinghouse, while Brookfield Renewable and its institutional partners will own the rest.
Westinghouse was acquired from Toshiba Corp (6502.T) by Brookfield Business Partners , an affiliate of Canadian asset manager Brookfield (BAMa.TO), out of bankruptcy in 2018, for $4.6 billion, including debt.
Brookfield Business said in a separate statement it expects to generate about $1.8 billion in proceeds from the sale of its 44% stake in Westinghouse, with the balance distributed among institutional partners. The deal is expected to close in the second half of 2023.
Last year, Reuters reported that Brookfield Business was exploring options including the sale of a minority stake in Westinghouse.
Brookfield Renewable and its partners will pay about $2.3 billion for the deal, whereas Cameco will incur equity costs of about $2.2 billion. Westinghouse's existing debt structure will remain in place.
Cameco, one of the largest suppliers of uranium fuel, said it would fund the purchase through a mix of cash, debt and equity.
<<<
---
>>> After a lengthy drought, could biotech M&A be on the upswing?
The second quarter was one of the busiest three-month periods for acquisitions in recent years. Some industry watchers expect that pace to continue.
Pharmadive
July 8, 2022
Jacob Bell
https://www.biopharmadive.com/news/biopharma-deals-mergers-acquisitions-2022-first-half/626798/
Mergers and acquisitions in the pharmaceutical industry were more abundant in the second quarter than during the same period in years’ past, an uptick in activity that could help the sector rebound from a historic downturn.
Between April and June, there were at least 14 biopharma acquisitions worth $50 million or more, a tally roughly two- to three-times larger than what was seen in that stretch in each of the last four years. And if megadeals like AbbVie’s 2019 takeover of Allergan weren’t factored in, this year’s second quarter would outrank the prior four in value, with approximately $23.4 billion spent on buyouts.
Almost half of that sum came from Pfizer’s $11.6 billion purchase of Biohaven Pharmaceuticals, the neuroscience-focused company that sells the migraine medication Nurtec ODT. But three other acquisitions also surpassed the billion-dollar mark, and involved smaller makers of vaccines and cancer drugs getting absorbed by much larger, multinational firms like Bristol Myers Squibb and GlaxoSmithKline.
This uptick comes after a somewhat prolonged dearth of dealmaking. In a January report, financial services firm Ernst & Young found that 2021 was one of the least active years for biopharma M&A in the last decade. At $108 billion, last year’s cumulative deal value was lower than the $128 billion recorded in 2020 and less than half the $261 billion seen in 2019, according to EY.
To some industry followers, the number and size of recent transactions may not be so surprising. Last year, analysts at the investment bank SVB Securities wrote that they expected the pace of biopharma dealmaking to either hold or increase in 2022.
Such predictions have hinged on several factors, with one being the amount of cash many would-be acquirers are sitting on. Pfizer, thanks in part to its coronavirus vaccine, ended the first quarter with $2.5 billion in cash and cash equivalents and another $21.4 billion in short-term investments. Swiss pharmaceutical giant Novartis, meanwhile, just sold off billions of dollars worth of stock in crosstown rival Roche.
Merck, maker of the COVID-19 pill Lagevrio and the blockbuster cancer therapy Keytruda, also had nearly $8.6 billion in cash and cash equivalents by the end of March. Merck may be looking to put that money to work, too, as The Wall Street Journal reported last month, and again Thursday, that the company could acquire Seagen, a Seattle-based cancer drugmaker currently worth more than $32 billion.
While Seagen’s share price has grown since the buyout talks became public, a broad downturn in the biotech stock market has deflated the valuations of many younger, smaller drug companies. Now, amid concerns that funding may be harder to come by, dozens of biotechs are reorganizing or shedding programs to save cash. In a June report, accounting firm PwC noted that more than 60 have announced layoffs this year, with several ending operations altogether.
Private biotechs are facing a tougher environment too, with venture financing numbers trending downward and little demand for initial public offerings.
But another effect of lower valuations, according to deal experts, could be more M&A. “With capital becoming harder to come by for most biotechs, pharma is in a good position to acquire many of these companies at a discount from their highs of just a couple years ago,” partners at PwC wrote in the report.
Throughout 2019 and 2020, biopharma buyers often paid at least double the market value of the companies they were acquiring. And though premiums have remained in the triple-digits for some deals this year, others like the Pfizer-Biohaven one or GSK’s purchase of Sierra Oncology fell in the range of about 40% to 80%. In some cases, like the buyouts of Radius Health and Epizyme, biotechs have sold themselves for prices at or near all-time lows.
Such deals suggest that while biotech executives “have been slow to accept lower valuations … more companies are willing to explore alternative means of financing as capital becomes harder to come by,” the PwC partners wrote.
If the recent deal spree continues, it may provide a boost to the biotech industry. M&A is one of the main ways investors gauge the health of the sector and their ability to secure returns, so increased activity could reinstill confidence.
Looking ahead, the PwC partners expect dealmaking to continue. They believe large pharmaceutical companies will pursue acquisitions to, among other reasons, bring in new drugs that can help offset the expected losses should some of their key products lose patent protection over the next several years.
“All of the stars are aligned for there to be a flurry of deals activity across all areas of the sector,” the partners wrote.
<<<
---
Occidental - >>> Here’s Why Warren Buffett Loves Oil Giant Occidental Petroleum
Bloomberg
August 19, 2022
https://finance.yahoo.com/news/why-warren-buffett-loves-oil-224739000.html
Famed investor Warren Buffett is steadily snowballing a stake in Occidental Petroleum Corp. in what could end up being his biggest-ever acquisition. His Berkshire Hathaway Inc. on Friday won approval to buy as much as 50% of the shares. Some investors believe it’s a step toward a full takeover, which may end up costing more than $50 billion.
Here’s why Occidental is attractive to Berkshire:
Oil
Inflation looks to be the mega-trend for the first half of the 2020s and crude oil is one of the best natural hedges out there. Russia’s invasion of Ukraine and a lack of investment in new oilfields over the past five years have hit supplies, leading to stagnant production profiles everywhere from OPEC to US shale. Meanwhile, demand for fossil fuels has been strong coming out of the pandemic even as governments push for a switch to clean energy.
With investments across the energy sector from utilities to solar power, Buffett claims to be a realist in the debate around fossil fuels. “People that are on the extremes of both sides are a little nuts,” he said at a Berkshire shareholder meeting in 2021.
Familiarity
Buffett first invested in Occidental in 2019 when the oil company was in a bidding war with Chevron Corp. to buy its crosstown Houston rival, Anadarko. Occidental CEO Vicki Hollub flew to Omaha, Nebraska, on the company’s Gulfstream V and convinced Buffett to add $10 billion to her war chest. It was enough to swing the deal and Chevron pulled out soon after. In exchange, Buffett got preferred shares yielding 8% annually plus warrants to buy more common stock at $59.62 apiece. Today, with Occidental at $71.29, those warrants would turn a profit of more than $900 million if exercised.
Value
Initially the Anadarko deal was a disaster because it loaded up Occidental’s balance sheet with more than $30 billion of additional debt right before the pandemic. Occidental’s market value went from $50 billion before the 2019 transaction to less than $9 billion toward the end of 2020 as oil prices crashed.
But on the flip side, this created a good value play for Buffett. When crude turned around late last year and was supercharged by Russia’s invasion of Ukraine, Occidental was best-placed to benefit. The stock is the best performer in the S&P 500 this year, up more than 140% compared with the index’s 11% decline.
“Oxy started this year heavily indebted with massive oil exposure,” said Bill Smead, who manages $4.8 billion at Smead Capital Management Inc. and is a top 20 shareholder in Occidental. Soaring crude prices mean “they’re now paying off that debt and gushing cash. It’s the best of all worlds.”
Cash
Too much cash has been Berkshire’s biggest investing challenge over the past few years. The conglomerate had about $105 billion on hand at the end of June. It is expected to generate about $8 billion in free cash flow each quarter for the next five years, according to Greggory Warren of Morningstar Research Services LLC. Inflation at the highest in 40 years is a great incentive to put that money to work.
Occidental would work better as a subsidiary of Berkshire than a stock holding “given the volatility that exists in the energy/commodity markets,” Warren said. “This could end up, though, evolving into a slow-motion takeover where Berkshire buys up to the stakes that FERC allows it to acquire until it can acquire Oxy whole.”
Shale
Occidental is not only one of the biggest producers in the Permian Basin, the largest US oilfield, but it also has one of the lowest costs with an oil price of just $40 a barrel needed to sustain its dividend. West Texas Intermediate currently trades at about $90 a barrel. Hollub has reined in the “drill-baby-drill” mentality that characterized shale for the first decade of its lifespan and is now prioritizing profits over production. Free cash flow hit a record $4.2 billion in the second quarter.
The Anadarko purchase may have been expensive, but it allowed Occidental to lift its land holdings in the Permian to 2.8 million acres, 14 times the size of New York City’s five boroughs combined. It also added steady, cash-flowing assets in the Gulf of Mexico and Algeria.
CEO
Buffett has a good personal relationship with Hollub, which began at the 2019 meeting in Omaha, brokered by Bank of America Corp. CEO Brian Moynihan. This year, the veteran investor praised Hollub after reading a transcript of Occidental’s Feb. 25 earnings conference call in which she pledged financial discipline even as oil prices were rising.
“I read every word, and said this is exactly what I would be doing,” Buffett told CNBC’s Becky Quick in “Squawk Box” in March. “She’s running the company the right way.”
Inflation Reduction Act
The oil industry mostly criticized the Inflation Reduction Act that President Joe Biden signed into law this month. The $437 billion legislation “discourages needed investment in oil and gas” and offers “the wrong policies at the wrong time,” the American Petroleum Institute said.
But Hollub was surprisingly upbeat, calling the bill “very positive.” That may have something to do with its expansion of tax credits for carbon capture, of which Occidental is a leading proponent. The company has plans to build the world’s biggest direct air capture plant which will command a tax credit of as much as $180 for each ton of carbon sucked out of the air.
<<<
---
Occidental Petroleum - >>> Why Warren Buffett Showed His Hand in Pursuit of 50% Stake in OXY
The Wall Street Journal
By Ryan Dezember
https://www.wsj.com/livecoverage/stock-market-news-today-08-19-2022/card/g6oQqfG2ShLVh8davJhk
Occidental Petroleum owns a power plant in Taft, La., that feeds an OXY chemical plant next door. Leftover power is sold on the local grid, which Berkshire Hathaway Energy plants also feed.
The Federal Energy Regulatory Commission ruled that since OXY's plant accounts for just 0.48% of the capacity connected to the region's grid, a combination with Berkshire "will not have an adverse effect on competition" in the local electricity market.
Warren Buffett's Berkshire had to ask, though, before beefing up its 20% stake to as much as half of OXY's shares. Now the market has gotten a rare glimpse of what the famous investor has up his sleeve.
<<<
---
Blackstone - >>> The private equity club: how corporate raiders became teams of rivals
Financial Times
by Antoine Gara
August 9, 2022
https://www.ft.com/content/aec70aab-7215-4fa7-9ee3-1224d967dc28?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
The industry was founded by mercenary dealmakers who bludgeoned opponents. But firms now nurture complex relationships with their competitors
When buyout groups Hellman & Friedman and Permira began stalking a takeover of business software giant Zendesk in February, they tried to bring in a third partner for what would be a large deal. They called Blackstone, a firm that manages more than $125bn in private equity assets and that they each knew well from previous transactions.
Blackstone was initially interested in Zendesk but in the end it passed on the investment. However, the firm’s involvement did not end there. When H&F and Permira eventually announced their $10.2bn acquisition of the software company in June, the press release did not name any of the Wall Street banks that would usually provide the bridge loans to complete such a deal.
Instead, H&F and Permira said that amid choppy capital markets they had secured more than $4bn of debt financing. The debt came from a group of would-be competitors led by Blackstone.
Firms like Blackstone and Apollo, another lender in the deal, made their names as swashbuckling takeover artists. The industry was founded from the 1970s to the early 90s by small teams of mercenary dealmakers, who then duelled with each other to win control of large corporations such as RJR Nabisco, Alliance Boots, and Philips Semiconductors.
The Zendesk takeover shows how deep the ties can run between leading private equity firms
Private equity firms have since grown to manage almost $10tn in assets and have become the dominant force in global financial markets.
But as the industry has expanded, its character has been transformed. Firms that once bludgeoned opponents now nurture complex business relationships with their competitors. Private equity has become just a fraction of their overall assets under management, with credit investing businesses now managing hundreds of billions of dollars, including providing loans for leveraged buyouts.
The result of these sprawling empires is that once heated rivals increasingly see the benefits of a level of co-operation between different business units that once seemed inconceivable.
“Private equity started 35 years ago as a dark art. Now it is an asset class,” Marc Rowan, chief executive of Apollo Global, told an audience earlier this year. “There are no permanent friends or permanent enemies anymore.”
With private equity deals now accounting for over 25 per cent of global M&A activity — a record market share — the collective power of the leading groups is starting to attract the attention of regulators.
Private equity takeovers, once rubber stamped by antitrust authorities, are now being treated with the scrutiny reserved for large corporations, competition watchdogs have told the Financial Times.
It is a striking reversal for a sector that has more often in the past been criticised by politicians for its ruthlessness rather than its clubbiness.
“When you have repeated relationships, you are just not going to go to war with the same ferocity,” says Josh Lerner, a professor at Harvard Business School, who has studied private equity for decades.
Relationships that run deep
The Zendesk takeover is illustrative of how deep the ties can run between leading private equity firms.
The origins of the takeover go back to 2016 when Permira invited H&F to make a minority investment in a call centre technology company called Genesys, which it had bought from Alcatel-Lucent four years earlier. H&F invested $900mn in Genesys at a $3.8bn valuation, more than double Permira’s initial investment.
H&F and Permira initially studied merging Genesys with Zendesk, according to sources directly involved in the deal. When the idea did not advance, they turned to Blackstone, which helped arrange more than $4bn in debt financing that is now the largest private financing on record.
For Blackstone, it meant supporting a deal led by two of its most important customers. Blackstone Credit, the buyout firm’s $230bn in assets lending arm, is a reliable lender to both firms. It provided the majority of $1.2bn in financing for H&F’s takeover of NPD Group in October 2021 and $2.2bn in debt for Permira’s take-private of cyber security group Mimecast two months later.
H&F co-led the largest leveraged buyout of 2021 alongside Blackstone, taking control of medical supplier Medline Industries for $34bn. A year earlier, the two firms struck an equally ambitious deal to merge their combined investments in human resources IT company Ultimate Software and cloud software specialist Kronos, in a $22bn deal.
To buy Zendesk, H&F and Permira raised billions in debt against a business that generated just $80mn in profits last year, far more than what regulated banks could offer, according to three people involved in the deal.
Blackstone, which considers H&F a skilled partner for takeovers, took part in the financing, as did Apollo, which financed more than $750mn of the takeover, and counts both firms among the 25 private equity firms to which it has lent over $40bn. Famed for its ruthless tactics with debtholders, Apollo now aspires to become a go-to financier for the deals organised by competitors.
“The zero-sum game mentality of old school dealmakers that always assumed that for them to win someone had to lose is really an outdated point of view,” says an executive at one of the industry’s largest global firms. “There are so many opportunities. Today you are competing and tomorrow you will bring them in as a partner on a deal. It is the new reality.”
By the 2008 crisis, buyout firms could not always afford to purchase on their own some of the companies they considered attractive targets, such as Toys ‘R’ Us
Aggressive outsiders
The modern day private equity buyout traces to Michael Milken’s Drexel Burnham Lambert, the investment bank that popularised the “junk bond”. Drexel financed small teams of dealmakers targeting corporate giants such as Disney, Texaco and then RJR Nabisco, the signature LBO of the go-go 1980s.
Milken, and many of Drexel’s clients, were considered aggressive outsiders, unafraid to gatecrash Wall Street.
“The Drexel guys that Milken was backing were pretty non-genteel types,” says a buyout executive who worked in that era. “It was like the Gold Rush. The guys who couldn’t make it in the city went off to look for gold.”
By the 2008 crisis, private equity had become part of the financial mainstream as it pulled off a string of ever-larger takeovers. These so-called “club deals” hinted at the willingness of some firms to co-operate out of self-interest.
Buyout firms, then privately owned partnerships almost exclusively focused on corporate takeovers, could not always afford to purchase on their own some of the companies they considered attractive targets — such as hotelier Hilton, utility TXU, retailer Toys “R” Us, and hospital chain HCA. However, by assembling consortiums of competitors that each contributed a slice of the equity, almost any deal became possible.
These club deals led to some legal battles. A 2007 civil lawsuit in Massachusetts led by a pension fund in Detroit accused 16 private equity firms of forming consortiums that rigged bids in sale processes.
The case centred on the $33bn LBO of HCA, which was won by Bain Capital, KKR and Merrill Lynch, after there were no other competing bids. Emails unearthed by lawyers showed competitors refraining from outbidding each other.
“I don’t want to be in a pissing battle with KKR at the same time we are teaming on other deals,” said David Rubenstein, one of Carlyle’s founders, in an email unearthed during the litigation.
These deals were not all successes. Toys “R” Us, for instance, fell into restructuring. Moreover, to settle the Massachusetts litigation, Goldman Sachs and Bain Capital paid $121mn, while KKR, Blackstone and TPG agreed to pay $325mn, all without admitting or denying guilt.
By the time of the financial crisis, club deals had mostly vanished as investors found themselves exposed to the same failing investments in multiple funds and called for an end to the practice.
But the crisis also opened a window for buyout firms to transform themselves into much broader operations that are shifting the balance of power in finance towards private markets.
Investment banks, hamstrung by new regulations like the 2010 Dodd Frank Act, were curtailed from holding risky assets such as low-rated debts, which has limited their ability to finance many deals. As a result, corporations and private equity buyers have had to seek new ways of issuing debt. Blackstone, Apollo, KKR and Carlyle stepped into the void.
They bought billions of non-performing loans from banks in the US and Europe, betting that the portfolios would stabilise. As markets recovered, they shifted to originating new loans, underwriting midsized private equity takeovers that banks would not finance.
It set off private equity’s march into new businesses such as lending, insurance-related investments, real estate and infrastructure, which were far from their original speciality in buyouts.
Blackstone acquired debt manager GSO in 2008, seeding its expansion into credit and insurance-based investments, which now comprise 28 per cent of the group’s $940bn in assets.
Apollo, under current chief executive Rowan, built an insurer called Athene that was designed to invest fixed-rate annuity premiums into complex debts, like senior loans. These credit investments are now Apollo’s biggest and fastest growing business.
In private lending markets, the fastest growth has come from financing software takeovers, like Zendesk, which banks cannot handle due to the level of leverage involved. Several other large software deals this year, like Thoma Bravo’s $10.4bn takeover of Anaplan, were financed by private lenders because the leverage ratios on the debt are beyond what banks are comfortable handling.
In these deals, lenders will “club up” by assembling a consortium of competitors, resembling the consortiums of the pre-crisis era.
These private financings have continued as interest rates rise — just as many investment banks have been refusing to make new lending commitments until loans from deals struck earlier in the year have been sold on. The result has been a halt in the market for bank-financed takeovers and the private lenders winning market share.
“The idea that we would work with KKR and Blackstone to provide debt for us once seemed like a crazy idea. Today, people don’t even think about it,” says the head of one private equity firm. “There are no clean lines. Everyone is a competitor, a collaborator and a partner.”
This web of relationships has changed the character of the industry. “It is costlier than ever to be a jerk,” says Steven Kaplan, an expert on private equity who teaches at the University of Chicago. “If they behave badly in one deal, they will be treated differently in the next deal.”
The ties stretch far beyond lending. The fastest way for buyout firms to deploy their nearly $2tn in “dry powder,” or funds they have raised that have yet to be invested, is to buy companies directly from other private equity firms. A record 442 of such deals worth $62bn were struck last year, according to Refinitiv.
These deals can close in less than three months, say bankers, versus as long as nine months to acquire a public company. They can also be expedient: sellers sometimes look to quickly lock in gains and show strong returns as they raise their next fund, notes one private equity firm executive.
“A lot of times you have good companies that a sponsor owns, but they need to sell to show dollars realised for their fundraising,” says the executive.
There has also been a surge in so-called “secondary buyout transactions,” where one private equity firm sells a large stake in an existing investment to another firm at a higher valuation.
One of the industry’s earliest major deals was H&F’s 2014 sale of a $750mn minority interest in Kronos, a seller of cloud-based time sheet services, to a group of buyers led by Blackstone, that were willing to take lower governance rights and leave H&F in control of the deal.
Five years later, H&F led a deal to acquire Ultimate Software for $11bn, bringing in Blackstone and GIC, its same partners on the Kronos stake sale. Blackstone’s debt arm co-led $900mn in financing for the riskiest piece of the deal’s $3.4bn total debt package, helping to get it over the line.
The two private equity firms then merged Ultimate Software with Kronos a year later, generating billions of dollars in gains, underscoring how close relationships can get deals done.
Can it last?
The first test of the private equity industry’s new co-operative structure was the coronavirus pandemic. Broad swaths of the global economy closed, threatening to create a wave of defaults for private lenders that had financed a flurry of takeovers.
What occurred instead was a mass forbearance as private equity borrowers and their lenders amended loans to give companies breathing room. To smooth the new and more lenient liquidity measures and show good faith, some borrowers added additional equity to the deals.
“The whole concept was we’re not going to foreclose,” says one borrower involved in numerous negotiations. “They’re in the business of ideally doing multiple deals with your portfolio companies. They know that if they act poorly, my job is to not show them future business.”
One such example was a company called European Wax Centre, an operator of hair removal salons that was acquired in 2018 by private equity firm General Atlantic with a $180mn loan from private lender Blue Owl. When the pandemic shuttered the company’s salons, Blue Owl voluntarily amended the loan to forestall a cash crunch and General Atlantic made an over $10mn cash infusion as a concession.
After the economy reopened, European Wax recovered and its debts were refinanced at par. Last year, the company went public, valuing General Atlantic’s stake at $639mn, several multiples of its original investment.
Young Soo Jang, a PhD student at the University of Chicago, has studied private lenders’ behaviour by examining over 200 deals that fell into distress during Covid.
He found private lenders were twice as likely as the broadly syndicated loan market to ask for borrowers to agree to inject new capital into deals, forestalling restructuring. Five per cent of distressed private deals led to bankruptcies, according to the research, half the rates of bank financed deals.
“A lot of the direct lenders put out a lot of capital?.?.?.?They were extremely nervous,” adds one executive involved in these deals. “Everyone benefited from the fact that there was such a sharp snap back in the economy.”
The global economy sidestepped a brewing financial crisis during the pandemic thanks to an unprecedented policy response.
But as financial markets enter another troubled moment amid the war in Ukraine and central bank tightening, the ties between firms will be tested again.
“This increased co-operation and cosiness is really a bull market phenomenon,” says Lerner, the Harvard professor, who expects falling markets will unearth new conflict as deals sour, pitting parties against each other.
However, the firms involved in the Zendesk financing insist these new relationships will not break.
“It is very hard to be a credible direct lender and a hostile investor,” says the head of one firm involved in the deal. Another adds: “We’re just trying to get our money back and get a return.”
<<<
---
>>> Blackstone to Buy Bulk Purchaser CoreTrust From HCA Subsidiary
Firm getting supply chain used by its companies, and rivals
Bet is competitors’ portfolio firms will stay with CoreTrust
Bloomberg
By Benjamin Robertson, Dawn Lim, and Kamaron Leach
August 10, 2022
https://www.bloomberg.com/news/articles/2022-08-10/blackstone-to-buy-bulk-purchaser-coretrust-from-hca-subsidiary?srnd=premium
Blackstone Inc. is buying a company that controls how a swath of businesses owned by private equity firms secure and pay for goods and services as varied as printers, pallets and postage.
The world’s largest alternative asset manager agreed to buy a majority stake in CoreTrust, a business that started within a supply arm for hospital giant HCA Healthcare Inc., Blackstone executives said. HCA’s HealthTrust subsidiary will continue to hold a minority stake in CoreTrust. A Blackstone spokesperson declined to comment on financial terms of the deal.
CoreTrust aggregates the buying power of its customers -- mostly companies backed by Blackstone and its investment rivals -- for a negotiated group discount with service providers for purchases spanning software subscriptions to forklifts. The deal may reverberate across private equity though, prompting some firms to reconsider whether to keep steering portfolio companies to CoreTrust, given the new ownership.
Blackstone is taking measures to keep their business. For instance, it won’t collect commissions from vendors anymore for referring portfolio companies to CoreTrust after the deal closes in coming months, according to a representative for the firm. New York-based Blackstone, which is making CoreTrust investment through its buyout arm, won’t have access to rivals’ trade secrets through the purchase.
Advantage of Scale
Blackstone is banking on CoreTrust’s customers to stay on given the advantage of economies of scale, and to hedge against inflation. It also plans to expand the company’s reach beyond its main clientele.
“As you become a bigger customer, you move to the top of the queue and get some benefits in supply chain certainty,” said Peter Wallace, Blackstone’s head of core private equity.
“Inflation is the biggest story in the country right now,” he said. “With this on the top of everyone’s agenda, it’s easier to get more people on it and drive more adoption.”
Representatives for HCA and CoreTrust didn’t immediately respond to requests for comment.
2004 Investment
In 2004, Blackstone invested in a hospital system network that used HealthTrust. The firm considered starting a group-purchasing business but ultimately asked HealthTrust to start a division to do it for them.
Blackstone has steered hundreds of portfolio companies to CoreTrust, which saved them almost $200 million over the years, said people familiar with the matter who asked not to be identified because the information was private. Blackstone doesn’t dictate where those businesses buy supplies, the people said.
Other clients have included portfolio companies of Onex Corp. and KKR & Co., according to CoreTrust’s website.
Bulk purchasing recognizes that “portfolio companies can unlock new value in each other” rather than be “a bunch of isolated, individual investments,” said Francois Mann Quirici, a founding partner at Nexus Associates, who advises buyout firms on how to take advantage of cross-portfolio linkages. Firms including Carlyle Group Inc. and Oaktree Capital Management have been exploring how to centralize procurement for their portfolio companies.
The strategy has generated extra fee streams for the private equity industry, who pocket money in exchange for matching up portfolio companies with group purchasers.
Commissions Questioned
Those types of commissions have attracted the attention of regulators and pension funds. During the Obama Administration, the US Securities and Exchange Commission examined the practice, calling out Welsh, Carson, Anderson & Stowe for failing to tell investors about money received for portfolio companies’ purchases. Welsh Carson, which settled with the SEC without admitting or denying any findings, declined to comment.
“Group purchasing organization has been a big part of the Blackstone strategy,” said Jeremy Smith, head of public sector at London-based consulting firm 4C Associates. “Now Blackstone has not only their own scale, but that of other private equity firms too.”
<<<
---
>>> Amazon is buying robot vacuum company iRobot for $1.7 billion
ZD Net
by Sabrina Ortiz
Aug. 5, 2022
https://www.zdnet.com/home-and-office/kitchen-household/amazon-is-buying-robot-vacuum-company-irobot-in-a-1-7-billion-dollar-deal/
Amazon is buying robot vacuum cleaner company iRobot in a deal valued at approximately $1.7 billion.
iRobot is best known for the Roomba, the autonomous vacuum cleaner that finds its way around household obstacles to vacuum floors completely on its own. It also makes robot mop devices, too.
Colin Angle, CEO of iRobot, says Amazon was the perfect fit for the company. "Amazon shares our passion for building thoughtful innovations that empower people to do more at home, and I cannot think of a better place for our team to continue our mission. I'm hugely excited to be a part of Amazon and to see what we can build together for customers in the years ahead," he said. He will remain as CEO once the transaction is completed.
Dave Limp, SVP of Amazon Devices, said that Amazon recognizes how much iRobot has done to make people's lives easier.
"Over many years, the iRobot team has proven its ability to reinvent how people clean with products that are incredibly practical and inventive—from cleaning when and where customers want while avoiding common obstacles in the home, to automatically emptying the collection bin," said Limp in the release. "Customers love iRobot products—and I'm excited to work with the iRobot team to invent in ways that make customers' lives easier and more enjoyable."
iRobot far from the first company Amazon has acquired to expand its smart home portfolio. In the last five years, Amazon acquired Blink Home, the security camera company, for an undisclosed amount and Ring, the camera doorbell company, for approximately one billion dollars. These acquisitions allowed the company to add security devices to its smart home ecosystem.
Amazon has been a leader in the smart home space with their Alexa Smart home technology, which allows you to control everything from lighting to security to televisions and thermostats with the sound of your voice.
iRobot and Amazon already had established a relationship when they partnered to make the Roomba and Braava jet robots compatible with Alexa in 2021. This partnership allowed customers to use voice commands to tell the robots to start or stop cleaning and to go back to its home base.
Meanwhile iRobot reported revenues of $455.4 million and a net loss of $31.5 million due to supply chain constraints in the fourth quarter of FY 2021. The company also said that it sold its 40 millionth robot during the final quarter of 2021.
<<<
---
>>> Cybersecurity Stocks To Watch: Private Equity Firms Target Sector
Investor's Business Daily
REINHARDT KRAUS
08/08/2022
https://www.investors.com/news/technology/cybersecurity-stocks/?src=A00220
You may think the time is right to move into cybersecurity stocks amid views they're better positioned if a recession hits the U.S. economy. Private equity firms continue to target the sector, with Thoma Bravo acquiring Ping Identity Holdings (PING) for $2.8 billion.
Thoma Bravo has also acquired cybersecurity firms SailPoint Technology, Proofpoint, Sophos and Barracuda. The private equity firm has invested in cybersecurity startups, such as Illumio.
Also, PE firm Permira in May completed its purchase of Mimecast for $5.8 billion. PE firms aren't the only acquirers.
Consolidation Impacts Cybersecurity Stocks
Google-parent Alphabet (GOOGL) on March 7 said it's acquiring cybersecurity firm Mandiant (MNDT) in an all-cash $5.4 billion deal. Mandiant will be part of Google's cloud computing business.
Also Google in January acquired Siemplify, a security orchestration, automation and response provider, for around $500 million.
"Increased acquisition activity is being spurred by depressed valuations in the current uncertain macroeconomy," said Cowen analyst Shaul Eyal in a report. "We believe that acquirers are increasingly seeking targets that demonstrate a balance of growth versus profitability and positive cash flow."
Meanwhile, the iShares Expanded Tech-Software ETF (IGV) climbed 9.5% in July, turning positive for the first time since March.
Earnings Reports Due For Cybersecurity Stocks
Earnings are starting to roll in for cybersecurity stocks. Check Point Software Technologies (CHKP) reported earnings on Aug. 1. CHKP stock fell on guidance.
Fortinet (FTNT) reported Q2 earnings, revenue and billings that topped estimates but the size of the beats disappointed. For the September quarter, Fortinet forecast sales of $1.12 billion, below estimates of $1.13 billion.
Palo Alto Networks (PANW) reports earnings on Aug. 22. Palo Alto Networks has been building a broad cloud-based services platform via acquisitions. Palo Alto Networks has spent more than $3 billion on 10 acquisitions over the past three years.
The IBD Computer-Software Security group ranks No. 110 out of 197 industry groups tracked.
According to a Morgan Stanley survey of chief information officers in July, cloud computing and security software remain at the top of priority lists, followed by business intelligence/analytics, digital transformation and artificial intelligence.
Bank of America in a recent report said cybersecurity stocks that deliver services via cloud computing platforms will be better positioned.
"We believe 'born-in-the-cloud' companies like Zscaler (ZS), Crowdstrike (CRWD) and SentinelOne (S) to be relatively resilient to any spending slowdown, also given how critical their solutions are to cyber defense efforts," said BofA analyst Tal Liani in a note to clients.
Corporate Spending On Cybersecurity
Earnings for CRWD stock are due Aug. 30. Zscaler reports earnings on Sept. 8.
Meanwhile, Qualys (QLYS) and Fortinet have dropped off the IBD 50 roster of growth companies. Qualys reports Q2 earnings on Aug. 8.
At an investor day for FTNT stock on May 10, Fortinet unveiled 2025 financial targets that call for billings of $10 billion and revenue of $8 billion, implying a three-year average growth rate of 22% for both metrics.
Cybersecurity stocks got a lift in February as Russia's invasion of Ukraine began. Analysts said attacks aimed at shutting down websites could increase.
"Expectations have lowered from pre-Q1 where Russia/Ukraine was still firmly in the spotlight, but are still higher than broader software into Q2," UBS analyst Roger Boyd said in a note. "We don't see stocks priced for negative guidance revisions."
Cybersecurity spending worldwide climbed 13% in 2021 to $172 billion, estimated market research firm Gartner, accelerating from 8% growth in 2020. In both 2022 and 2023, Gartner forecasts 11% growth in cybersecurity spending.
Further, Congress has finally passed legislation funding infrastructure projects, which is expected to include funding for federal, state and local cybersecurity infrastructure.
Ransomware remains a big threat, though fewer highly publicized incidents occurred in the back half of 2021.
The rise of cryptocurrency Bitcoin has been linked to a spike in ransomware attacks. In ransomware attacks, hackers take over computer systems, encrypt files and demand digital payment to restore access to critical data.
Cybersecurity Stocks With High Composite Ratings
Cybersecurity stocks with Composite Ratings above 90 include Qualys, Fortinet and Palo Alto Networks.
The Composite Rating is a blend of the other five IBD stock ratings: the earnings per share or EPS Rating, Relative Price Strength Rating, Accumulation/Distribution Rating, Industry Group Relative Strength Rating and the SMR Rating.
The latter measures sales growth, profit margins and return on equity. The all-encompassing Composite Rating helps investors easily measure the quality of a stock's fundamental and technical metrics.
No security stocks currently are members of the IBD Leaderboard. It's IBD's curated list of leading stocks that stand out on technical and fundamental metrics.
Hot Cybersecurity Startups Eye IPOs
And initial public offerings are on the table. SentinelOne's IPO raised $1.2 billion. SentinelOne is a rival of CrowdStrike.
Meanwhile, analysts say Netskope, Illumio and Menlo Security are among cloud security startups that could launch IPOs. Netskope in early July raised $300 million at a valuation of $7.5 billion.
Analysts say a new wave of startups seems to be taking share from industry incumbents.
Darktrace (DARK) launched its IPO on the London stock exchange in April. Darktrace utilizes self-learning artificial intelligence tools in security automation.
Further, consolidation may be coming in the cybersecurity industry. Okta (OKTA) in early 2021 acquired privately held Auth0 in a $6.5 billion, all-stock deal. Also, Okta is expanding into new security markets to take on CyberArk Software (CYBR) and SailPoint.
Microsoft Stock A Big Player In Cybersecurity
Also, Microsoft (MSFT) has moved into this space. The software giant recently disclosed that its cybersecurity revenue tops $10 billion annually. With 400,000 customers, Microsoft's computer security franchise is growing at more than 40%, the company said.
Microsoft in July 2021 acquired RiskIQ, a security threat management company. Bloomberg reported that Microsoft paid around $500 million. Microsoft also bought CloudKnox Security in July.
In addition, Microsoft is integrating more security tools into its cloud-based Office 365 software. As it expands cloud-based security services, Microsoft could pressure more industry incumbents, such as Okta, CrowdStrike, and Splunk (SPLK).
"Microsoft is clearly pitching itself as offering a full security suite, a competitive advantage as customers increasingly want a unified view of threats," UBS analyst Karl Keirstead said in a recent note.
Cybersecurity Stocks: Wide Range Of Products
Further, it behooves an investor to know which cybersecurity stocks address ransomware, phishing or other kinds of cyberattacks.
Meanwhile, CrowdStrike uses machine learning and a specialized database to detect malware on laptops, mobile phones and other devices that access corporate networks. In addition, many software companies are using artificial intelligence to get a competitive edge.
In addition, Zscaler is the biggest provider of cloud-based web security gateways that inspect customers' data traffic for malware.
SailPoint, an identity management software maker, is among companies that garner more than 10% of revenue from government agencies.
Coronavirus Outbreak Boosted Demand For Cloud Security
Other cybersecurity firms with a sizable government business include Tenable Holdings (TENB), Rapid7 and CyberArk. Tenable in 2021 acquired France-based Alsid, which focuses on identity access management.
In addition, Rapid7 and Qualys specialize in vulnerability management services.
Amid the rapid global spread of Covid-19, many companies instructed employees to work from home. That has increased demand for computer security products that support remote work.
The coronavirus emergency and shift to remote work has accelerated the growth of cloud-based network security. So the industry now has a new term for the infrastructure that supports distributed workers and branch offices.
It's spelled SASE — pronounced "sassy" — and it stands for Secure Access Service Edge.
SD-WAN Technology Changes Security Needs
Corporate America has hiked tech spending on security aiming to protect intellectual property as well as consumer privacy. Hackers continue to steal credit card data and intellectual property.
Spending on security technologies has evolved as companies shift business workloads to cloud computing service providers. Amazon Web Services, part of Amazon.com (AMZN), is the biggest cloud services firm. Amazon looms as a potential rival as it builds more security tools into its cloud services.
Also, Fortinet competes with Palo Alto Networks and others in the firewall security market. Firewalls reside between private networks and the internet. They block unauthorized traffic and check web applications for malware.
As large companies shift to off-premise cloud computing services, one view is that firewall technology will play a lesser role. Fortinet has targeted software-defined wide area networks, or SD-WANs, an emerging computer networking technology.
Aiming to catch-up in SD-WAN technology, Palo Alto Networks acquired startup CloudGenix.
Cybersecurity Products Battle Ransomware, Phishing
Cybersecurity stocks span a wide-range of products and services. In addition, some security vendors are shifting to software-based subscription business models from selling hardware appliances. Among them, Proofpoint specializes in email and data-loss protection.
Meanwhile, hackers often aim to compromise networks by targeting employees or management who have administrative access. CyberArk manages privileged accounts. In addition, Okta provides identity management services.
To slow down hackers, more companies are focusing on internal security threats though a strategy known as Zero Trust. In addition, traditional security measures aim to keep the bad guys out of corporate networks. Further, network firewalls focus on intruders from the public internet.
Zero Trust cybersecurity models focus on internal threats, such as hackers stealing someone's security credentials. Security firms verify the identity of network users and limit access to applications.
CrowdStrike, Okta, Netskope and Proofpoint recently formed a Zero Trust alliance. Targeting Zero Trust security, Cisco Systems (CSCO) in 2018 acquired Duo Security for $2.35 billion.
Artificial Intelligence Changing Cybersecurity Market
Also, many fast-growing cybersecurity firms are in the endpoint market. Their tools detect malware on laptops, mobile phones and other devices that access corporate networks.
Further, CrowdStrike's initial public offering in June 2019 raised $612 million, one of the largest cybersecurity offerings. CrowdStrike's rivals include VMware's (VMW) Carbon Black, Palo Alto and startup Cybereason.
The "Human Element" causes at least 75% of cyber breaches, according to a new study by Cowen Research and Boston Consulting Group. Many companies have stepped up employee training to deter ransomware attacks and other threats. Cowen favors Cloudflare (NET), Fortinet, CrowdStrike and KnowBe4 (KNBE).
In addition, state-sponsored hackers and cybersecurity firms are both using artificial intelligence to get an edge.
Artificial intelligence should improve computer security tools by speeding up incident responses. It could help thwart email-delivered ransomware or swarming botnets that knock out access to websites.
<<<
---
>>> Private equity buying up public companies at record pace during bear market washout
Yahoo Finance
by Alexandra Semenova
August 2, 2022
https://finance.yahoo.com/news/private-equity-buyouts-public-companies-120030634.html
Private equity firms are snapping up public companies at a frenzied pace amid a washout in equity markets that has sent valuations plummeting.
In the first half of 2022, buyout funds — which specialize in acquiring a controlling interest in a target company — announced or completed roughly $110 billion dollars in take-private deals globally, data from Preqin showed. The figure places this year’s deal value on pace to surpass the record total of $181 billion in 2021.
The rush by private firms to seize and de-list public names follows a sell-off in U.S. stocks that sent the S&P 500 and Nasdaq Composite into bear markets in the first half of this year, with high-flying technology names hit hardest. In July, risk appetite improved with the S&P 500 and Nasdaq gaining 9% and 13%, respectively.
This decline in public markets didn't dent the private equity industry's stock of dry powder, or capital committed by investors but not yet deployed by PE funds. As of June, buyout funds were sitting on $873 billion in dry powder, up slightly from $870 billion at the end of 2021.
North America saw public-to-private deal value hit $96 billion in the first six months of the year, compared to $118 in all of last, per Preqin.
Notable buyouts closed this year include Apollo Global Management’s roughly $7 billion agreement to acquire auto-parts maker Tenneco (TEN) and Blackstone’s purchase of PS Business Parks for $7.6 billion.
In the software space, Thoma Bravo has been the market leader, having taken part in buyouts worth $42.4 billion since the start of the 2021. Thoma Bravo's deals include a $10.7 billion takeover of Anaplan and a $2.6 billion deal to acquire Bottomline.
Brookfield Asset Management, Clayton Dubilier & Rice, and TPG Capital were also high on the list of buyout giants swallowing up companies this year.
Companies in the technology sector, software in particular, have been prime targets, according to Preqin.
“Large declines in public market valuations didn’t result in the situation we see here in 2008, where average deal values are rising amid market declines – nor is a pattern apparent in the years following,” Preqin said. “Moreso, the corresponding rise in relative valuations in 2021, and fall in 2022, also appeared to have little impact on fund managers’ appetite for these deals.”
“More likely is the case that these software companies are future-proof,” Preqin noted.
Activist investor Elliott Investment Management has targeted Pinterest (PINS) and PayPal (PYPL), stocks that have both suffered heavy losses since late 2021.
On Monday, Elliott revealed it had become the largest shareholder in Pinterest and issued support for the company's new CEO Bill Ready, news that sent shares up as much as 19% in after hours trading.
In an interview with Goldman Sachs earlier this year, ARK Invest founder and CEO Cathie Wood said she viewed companies trading at low valuations getting bought out as the biggest risk to her firm.
"So we will fight tooth and nail against larger companies if they try and pluck these companies up for their superior assets at bargain-basement prices," Wood said.
The time to fight, it seems, has begun.
<<<
---
>>> China buys America’s largest pork processor
07-06-2013
https://www.pigprogress.net/pigs/china-buys-americas-largest-pork-processor/
China buys America's largest pork processor
Last month China’s largest meat processor, Shuanghui International Holdings Ltd., agreed to pay USD $4.7 billion to acquire Smithfield Foods, Inc., the world’s largest hog farmer and processor. The deal is the biggest Chinese takeover of an American company in history.
The mega-pork deal immediately caused hand-wringing and outrage among Americans who fear growing Chinese dominance in the global economy. However, many analysts grudgingly agree the deal will be good for Smithfield, good for the US pork sector… and potentially great for the US beef industry if political leaders manage to leverage the deal to force changes in China’s trade policies.
Smithfield has twice as much revenue as its Chinese suitor, but sports a much smaller market value. China’s consumers are becoming wealthier and are adding more pork to their diet, while the market for pork in the US is stagnant.
The US pork industry is already highly concentrated, with Smithfield and four other companies controlling nearly three-quarters of America’s pork processing industry. Any US company that had coveted Smithfield would have had to face government antitrust hurdles. Shuanghui will face regulatory scrutiny through the Committee on Foreign Investments in the US, which looks closely at these acquisitions.
China owns USD $1.2 trillion of US federal debt, the most by far of any foreign nation. But this has nothing to do with America’s national debt. It has everything to do with building a better supply chain that moves American pig meat into the mouths of prosperous, happy Chinese customers. The US pork industry has struggled under the weight of high corn prices, which amount to around two-thirds the cost of raising a pig.
Scaling up
The deal was announced even as the Chinese government publicly committed to scaling up its own domestic pork production. Xiaoping Zhang, country director for the American Soybean Association in Beijing, says China’s backyard farms account for 40% of the country’s pork production. Small-scale inefficiencies make it expensive to grow a hog in China. Herd health has become a problem, so many small-scale farmers left the business.
“When these backyard farmers quit, it caused higher prices, and that was incentive for outside investment from both industry and the Chinese government,” says Zhang.
China’s government hopes that, by 2015, 80% of China’s pork will come from so-called ‘scaled-up’ domestic farms that will produce 500 pigs per year, compared to today’s average small-scale output of 50 pigs per farm per year.
Trade opportunities
Smithfield now produces half its hogs without the feed additive ractopamine, a lean muscle promoting drug that has been banned in China and Russia. This deal, combined with the racto-free pig production, should allow Smithfield to ship even more pork to China.
The acquisition provides a unique opportunity for American political leaders to pressure China into trade reforms. They want China to relax its ban on ractopamine, clearing the way for even more pig meat imports; and lift its 10-year-old ban on US beef imports.
“If you can’t leverage pressure on China now, when can you?” asks Steve Kay, editor and publisher of Cattle Buyers Weekly. “It’s a good opportunity.”
China’s ban on US beef was the result of a BSE case 10 years ago. The Smithfield deal coincides with the World Organization for Animal Health (OIE) decision to grant the U.S. its “lowest risk” status for BSE. (ie - Mad Cow Disease)
“China is not alone in using the decade-old BSE case against the U.S.,” says Kay. “Twenty-two countries still have full or partial bans on U.S. beef as a result of a single 10-year-old case of BSE. These are trade barriers because they are not taking into account science, especially since OIE has recognized U.S. beef as negligible for BSE risk.”
Unlikely bedfellows
While China and the US don’t always see eye to eye politically, the Smithfield deal further nudges the world’s two superpowers to get along. It means China has a vested interest in the well-being of the American economy.
The Smithfield deal will help China get what it desperately needs: respect, through the Smithfield brand. Chinese officials have been stung over and over by food safety scandals and were utterly embarrassed earlier this year when dead pigs were found floating in rivers near Shanghai.
Smithfield’s superior technology, phytosanitary measures and efficiencies will help China move its dubious food safety policies more in line with the western world. America’s pork production has been refined over decades into a system of mass production similar to making cars or televisions. Last year, 62% of the hogs in the US were raised on farms with at least 5,000 head, according to USDA. They’re often housed in vast, climate-controlled buildings, fed specialised diets of corn and soybean meal, and processed into bacon and ham in highly mechanized factories designed to ensure the meat is free of disease and contamination.
Smithfield plants have capacity to slaughter as many as 110,000 hogs a day. Its control of each stage of production helps the company trace back and address any problems with pathogens. “Their traceability is superb,” says John Mabry, an Iowa State University professor who specializes in swine genetics.
China, according to the US Meat Export Federation, has some 14,720 pig slaughterhouses compared with about 600 in the US
Last year the US sent 431,145 metric tons of pork worth $886 million to China. The deal could strengthen US pork prices as pork exports increase. That, in turn, will take more pork off the US domestic market and potentially raise the price of live hogs.
It’s positive for Smithfield and the US pork industry. American grillers may not be as thrilled.
<<<
---
$GTVH partners Lelantos Holdings and Electryone Advisors in the news this week. Note the discussion of the upcoming merger with GTVH in this announcement:
Lelantos Holdings, Inc. Announces a Completed Stock Symbol Change and Formal Partnership with Electryone Advisors
July 12, 2022 (Globe Newswire)
EQNX::TICKER_START (PinkSheets:LNTO),(Pinksheets:LNTO),(Other OTC:GTVH), EQNX::TICKER_END via InvestorWire -- Lelantos Holdings, Inc. (OTC PINK: LNTO) ("Lelantos" or the "Company"), formerly ProConcept Marketing Group, Inc., is pleased to announce that its stock symbol has officially changed from PRMK to LNTO which went into effect on July 7, 2022. The Company has been supported by its partner, Golden Triangle Ventures, Inc. (OTC Pink: GTVH) throughout the entire process while working diligently over the past year to accomplish many milestones. As the Company recently updated all of its financials to become current in its reporting obligations with OTC Markets, it has now accomplished its name and symbol change and is actively working to finalize its anticipated merger. This milestone will allow Lelantos to provide further value and transparency to its shareholders as they drive several projects to the forefront and execute a number of exciting accomplishments the Company has been working towards. Management looks forward to its mutually beneficial and synergistic working relationship with Golden Triangle Ventures as they continue to advance together on many fronts. This includes the recent partnership both companies have now secured with Electryone Advisors, an up-and-coming sustainable energy and microgrid design company.
Joshua Weaver, COO of Lelantos Holdings, stated, "Reaching the incredible milestone of realizing our symbol change is the culmination of more than 16 months of dedicated work by a large team. We are especially grateful for the support of Golden Triangle Ventures, which has guided us through the entire process. The whole company is incredibly excited to further provide value to all of our shareholders as we complete our merger and prepare to disclose the details of multiple projects that we have been working on, including mutual opportunities with Golden Triangle Ventures."
Lelantos Holdings has secured a compelling partnership with Electryone Advisors as an intricate factor in managing their green microgrid projects. Lelantos' North American and international presence will contribute as a stable infrastructure for Electryone to manage a high level of demand from clients of large, major corporations to city-wide and governmental organizations, as well as underdeveloped communities that are exploring a stable and green energy source. Electryone Advisors is currently retained on more than 200 microgrid projects to reduce carbon emissions while providing green energy solutions and will employ Lelantos Holdings for services that will assist with capital deployments, marketing consultation, and managing installation processes that include permitting and construction.
While Lelantos Holdings manages these processes, Golden Triangle Ventures will complement these activities by bringing large-scale projects to the table and providing a multitude of client management services for the contracts they originate.
Electryone is currently designing projects for a large international corporation and is in negotiations with major hotels, grocery, big box stores and casino chains. Electryone Advisors offers a unique competitive advantage by providing their customers with the tools - including a robust and sophisticated monitoring and control system that provides detailed analytics to measure carbon emissions - to meet energy demands and:
-- Immediately save 20% of their yearly spend
-- Lock into a 10-year fixed payment which prevents the yearly 3% - 5% + market increase and guarantees they will never encounter rolling power outages
-- Have a direct path to energy savings
-- Take control of their energy needs
-- Lead their business to a green future of carbon-neutral energy
Electryone Advisors website: http://www.ElectryoneAdvisors.com
Nathan Puente, CEO of Lelantos Holdings, stated, "The powerful relationship we have garnered with Electryone Advisors has the potential to fuel our company and drive growth for years to come. With several Electryone projects coming online in the near future, we will be rapidly advancing our revenue generation through these partnerships, which will enable us to invest in the other divisions and projects we have in the works. We feel honored and blessed to have been given this opportunity and look forward to mutually beneficial growth with Electryone while advancing both of our corporate goals through this wonderful partnership."
President Steve Mitchell of Electryone Advisors states, "We are excited about the partnership with the Lelantos group as they have already solidified our presence for Electryone to assist many different facilities. Lelantos will be an intricate foundation for Electryone in assisting and managing key processes that allow us to open new sales opportunities, provide higher visibility to the product, and deliver synergistic value to our operations."
About Lelantos Holdings
Founded in the spirit of "Solution Hunting," Lelantos Holdings' innovative business structure is purpose-built to acquire or joint venture with established entities in strategic market sectors. Lelantos is eager to expand its multifaceted presence to a public platform with a mission to create a diversified group of businesses at the forefront of innovation and foster an environment for accelerated growth and success, contributing to our shareholder's investment portfolio.
Pursuing business development through strategic innovation, Lelantos Holdings focuses on emerging technology in traditional markets to foster innovation and advance technological developments to positively impact our communities within the specific industries in which the company works:
-- Agricultural Technology & Consultation
-- Sustainable Energy
-- Business Development & Marketing
-- Medical Technology
Lelantos Holdings website: http://www.Lelantosholdings.io
FORWARD-LOOKING INFORMATION
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the company's business, projects and joint ventures; (iv) execution of the company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the company's projects; (vi) completion of the company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our company website, www.LelantosHoldings.io, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our company to review the information we post on the company website.
CONTACT INFORMATION
Lelantos Holdings, Inc.
Josh@lelantosholdings.io
Corporate Communications
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$GTVH Merger with Partner Lelantos Holdings coming up...
Golden Triangle Ventures, Inc.@GTV_Inc
We are proud to share a major milestone accomplished for our partners at Lelantos Holdings, their stock symbol has officially changed to $LNTO. Now that this is done, look forward to the official merger and many developments within both of our companies. $GTVH
Twitter Link:
https://twitter.com/GTV_Inc/status/1545051776788795395
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. (GTV) is a multifaceted consulting Company pursuing ventures in the health, entertainment, technology, fulfillment, and food & beverage industries, with many additional projects being developed that provide synergistic values to these divisions. The Company aims to purchase, acquire and/or joint venture with established entities that management can assist and help develop into unique opportunities. Additionally, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion for and commitment to these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services.
http://www.GoldenTriangleInc.com
In $ILIM I trust.
>>> 2 Warren Buffett Stocks That Are Absolutely Trouncing the Stock Market
Motley Fool
By Keith Noonan
Jul 5, 2022
https://www.fool.com/investing/2022/07/05/2-warren-buffett-stocks-that-are-absolutely-trounc/
The market has been brutal in 2022, but these Buffett-backed stocks are up big.
Berkshire Hathaway has returned to trouncing the market in 2022. Roughly halfway through the year, CEO Warren Buffett's company is down roughly 9%, while the S&P 500 index has slid roughly 21% across the stretch.
The investment conglomerate's year-to-date performance might not sound like cause for celebration, but it looks pretty good in context, and the company has some holdings putting up very strong performance amid the challenging backdrop. Read on for a look at two companies in the Berkshire Hathaway portfolio that are posting eye-catching performance despite the tough market conditions in 2022.
1. Occidental Petroleum
Berkshire Hathaway helped finance oil company Occidental Petroleum's (OXY -1.30%) acquisition of Anadarko Petroleum in 2019 through a roughly $10 billion investment. With the oil and gas market having rebounded from pandemic-related headwinds and now benefiting from record pricing levels, Buffett and Berkshire have ramped up their investment in Occidental.
Despite the tough backdrop for the market at large, Occidental's share price has more than doubled this year. It's not hard to see why investors are excited. With energy prices surging, expectations for this year's earnings have soared, and the jump in expected profits for next year is even more eye-catching.
The Oracle of Omaha seems to be betting that oil prices will remain high in the near future. Buffett loaded up on more Occidental Petroleum shares in the first quarter and, as disclosed in recent filings, has continued to add to its position in the company. Occidental currently accounts for roughly 3.6% of Berkshire's stock portfolio and stands as Berkshire's sixth-largest stock holding.
Buffett's company currently owns roughly 16.4% of the energy company's outstanding shares, and some investors think that Berkshire may be on track to acquire Occidental outright. In addition to its stock position, Berkshire also holds Occidental warrants, giving it the ability to purchase more stock at a price of roughly $59.62 per share. If Buffett opts to exercise those warrants, Berkshire would own a roughly 25% stake in the oil company.
With signs suggesting that gas prices are likely to remain high and a potential buyout on the table, Occidental could continue to significantly outperform the broader market in the near term.
2. Activision Blizzard
Berkshire Hathaway initiated a position in Activision Blizzard (ATVI -0.61%) shortly before Microsoft announced in January that it had signed a deal to acquire the video game publisher for $68.7 billion. Provided the deal goes through, it will become Microsoft's largest-ever acquisition.
As of Friday's close, Activision Blizzard is up 18% year to date and 20% since the announcement of the deal with Microsoft. However, with Activision's stock currently priced around $78 per share and Microsoft set to buy the publisher for $95 per share in an all-cash deal, the stock still has 21% upside at current prices. The deal is expected to close in the first half of 2023.
At its annual shareholder meeting, Berkshire revealed it had purchased even more of the game company's stock -- signaling high conviction in the likelihood of the deal going through. With its ample cash reserves and dependable management team, Microsoft is a reliable purchaser, and the all-cash nature of the deal means that investors won't be exposed to potential fluctuations of the tech giant's share price in the event of ongoing market volatility.
On the other hand, the acquisition still needs regulatory approval, and some investors are betting that antitrust issues will ultimately cause it to fall apart. While Microsoft has plenty of strong competition in both the gaming industry and broader technology space, the fact that Activision Blizzard can be purchased at such a significant discount compared to the buyout price makes it clear the market believes there is still significant risk here.
<<<
---
>>> invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
Yahoo Finance
F-star Therapeutics, Inc.
June 23, 2022·
https://finance.yahoo.com/news/invox-pharma-acquire-f-star-113000697.html
Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwide
The transaction demonstrates the strength of F-star’s differentiated bispecific antibody technology and provides backing from a top 40 global pharmaceutical company to accelerate growth and unlock potential
F-star’s unique next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharm’s existing capabilities and reinforces its global oncology pipeline
LONDON, June 23, 2022 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), focused on research and development (R&D) and business development activities outside of China, and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that the companies have entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. The transaction has been unanimously approved by the invoX and F-star Boards of Directors and is expected to close in the second half of 2022.
F-star’s proprietary platform technology pioneers the use of tetravalent (2+2) bispecific antibodies that enable the simultaneous targeting of two different antigens and a unique set of pharmacology to deliver focused, potent and safe immune activation in the tumor microenvironment. Four programs are progressing in clinic, three based on F-star’s tetravalent platform and one next generation STING agonist, with multiple further undisclosed programs in development. These programs represent potentially first- and best-in-class drug candidates for many areas of unmet medical need, including patients with cancer and other serious diseases who have few other options available. Leveraging its modular antibody technology, F-star has forged collaborations with major international biopharma companies across a wide range of therapeutic areas including oncology, immunology and neurology.
invoX, established in 2021 in the United Kingdom, is Sino Biopharm’s international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics. F-star will form a key element of invoX’s strategy to accelerate Sino Biopharm’s development of innovative medicines to transform the lives of patients worldwide, complementing its existing R&D platforms and pipeline.
Ben Toogood, Chief Executive Officer of invoX commented: “Today’s proposed acquisition is aligned with invoX’s strategy to become a fully integrated biopharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs, worldwide. We are excited to welcome F-star employees and look forward to working with them as we invest in the company to progress and grow its clinical pipeline to realize the full potential of the platform.”
Eliot Forster, Chief Executive Officer of F-star said: “We believe our tetravalent bispecifics offer the best approach to tackle hard-to-treat cancers and other serious diseases, with the ambition to deliver longer and improved lives for patients. Today’s announcement is good news for F-star, for our shareholders and, of course, for patients. This transaction enables greater and longer-term opportunities to develop the F-star platform and accelerate delivery of our novel medicines as we work together towards a future free from cancer and other serious diseases. I’d like to thank the fantastic team at F-star as well as our partners for all their hard work, support and dedication and I’m delighted to share this exciting development.”
Transaction Terms
Under the terms of the merger agreement, invoX, a wholly owned subsidiary of Sino Biopharm, will commence a tender offer within the next 10 business days to acquire all of the issued and outstanding shares of F-star common stock for a price of US$7.12 per share in cash upon the completion of the offer. The transaction is expected to complete in the second half of 2022, subject to certain customary closing conditions, including the tender by F-star stockholders of greater than 50 percent of the issued and outstanding shares of F-star common stock and required regulatory approvals, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. Following the closing of the tender offer, invoX will acquire any shares of F-star that are not tendered in the tender through a second-step merger under Delaware law at the tender offer price.
Advisors
PJT Partners is acting as financial advisor to invoX, and Morgan Stanley & Co. LLC is acting as financial advisor to F-star. Shearman & Sterling LLP is serving as legal counsel to invoX and Sino Biopharm and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as legal counsel to F-star.
About invoX Pharma
invoX Pharma was incorporated in March 2021 and is a wholly owned subsidiary of Sino Biopharm, a global top 40 pharmaceutical company with more than 24,000 employees. United Kingdom-based invoX is Sino Biopharm’s international expansion platform, focusing on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics. At its core, the Company aspires to improve patients’ lives by creating access to innovative medicine.
For further information about invoX Pharma, please visit: https://invoxpharma.com/.
About Sino Biopharm
Sino Biopharm, together with its subsidiaries, is a leading, innovative research and development driven pharmaceutical conglomerate in China, with a business scope that is vertically integrated including research and development, manufacturing and sales and marketing infrastructure. The Company’s product offerings include a variety of biologics and small molecule drugs, and in therapy areas that include hepatology, oncology, cardiovascular and cerebrovascular diseases, orthopaedics, digestive and immune and respiratory diseases.
For further information about Sino Biopharm, please visit: http://www.sinobiopharm.com/.
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases, through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.
F-star’s four clinical programs are:
FS118: Rescuing CPI treatment failures & Improving outcomes in CPI naïve
A dual checkpoint inhibitor targeting PD-L1 and LAG-3. Phase 2 PoC trial underway in head & neck PD-1 acquired resistance patients as well as in CPI-naïve NSCLC & DLBCL.
FS222: Improving outcomes in PD-L1 low tumors
A CD137 (4-1BB) stimulator and PD-L1 inhibitor, with superior potency seen in pre-clinical activity. Phase 1 trial underway.
FS120: Improving CPI and chemotherapy outcomes
A conditional OX40/CD137 (4-1BB) dual agonist, with broad potential for combination. Phase 1 trial underway.
SB 11285: Improving CPI outcomes
A second generation STING agonist with Phase 1 monotherapy and PD-L1 (atezolizumab) combination trial underway.
<<<
---
>>> NortonLifeLock Drops 12%; 206 ETFs Affected
ETF.com
March 16, 2022
by Ben Kissam
https://www.etf.com/sections/features-and-news/norton-lifelock-drops-12-206-etfs-affected
NortonLifeLock Inc. (NLOK) dropped more than 12% on Wednesday after the U.K.'s Competition and Markets Authority (CMA) announced its intent to begin phase 2 investigations regarding Norton's proposed merger with Avast, a rival cybersecurity company.
The deal, worth between $8.1 billion and $8.6 billion, was supposed to close in February, but to go through, it needed approval from both Spain (which it received) and the U.K. It is now likely to be delayed another several months, and may not conclude until fall, at the earliest.?
Currently, 206 ETFs hold NLOK shares.?
The Global X Cybersecurity ETF (BUG) has the greatest exposure to NLOK, at 5.74%; followed by the TrueShares Low Volatility Equity Income ETF (DIVZ), with 4.03%.
From there, percentages drop off slightly, with the ETFMG Prime Cyber Security ETF (HACK) at 2.61%, followed by the ASYMshares ASYMmetric S&P 500 ETF (ASPY), at 2.34%; and the First Trust US Equity Dividend Select ETF (RNDV), at 2.20%.
BUG and HACK have seen the greatest 30-day percentage changes as holders of NLOK, at 7.83% and 3.99%, respectively.
A total of 64.3 million shares of NortonLifeLock are held in exchange-traded funds, comprising roughly 11% of the total outstanding shares.?
The top five ETFs with the most NLOK shares overall are not the funds with the most significant exposure but large, broad-based ETFs.
The SPDR S&P 500 ETF Trust (SPY) holds 6.24 million shares, while the iShares Core S&P 500 ETF (IVV) and the Vanguard S&P 500 ETF (VOO), which both track the same index as SPY, hold 4.97 million and 4.01 million shares, respectively.
Interestingly, despite the S&P 500 Index being known as a mostly large cap benchmark, the Vanguard Mid-Cap ETF (VO) holds 4.19 million shares of the stock. Meanwhile, the Vanguard Total Stock Market ETF (VTI) holds 3.38 million shares.
Cap-weighted ETFs are the top strategy holding Norton shares, with 45 funds, but multifactor ETFs and active management ETFs are also involved, with those funds holding NLOK numbering 34 and 27, respectively. ESG ETFs represent 21 funds and fundamental ETFs represent 18 funds, rounding out the top five.
About The Company
NortonLifeLock announced in August 2021 its plans to merge with Avast, a Czech software company. In its initial release, the companies said the merger "has compelling strategic logic and represents an attractive opportunity to create a new, industry leading consumer Cyber Safety business."?
“With this combination, we can strengthen our cyber safety platform and make it available to more than 500 million users,” said Norton CEO Vincent Pilette, when the deal was announced.
NortonLifeLock's products primarily focus on internet identity protection, whereas Avast's products aim to ward off viruses, phishing scams and other spam threats.
Although Avast's headquarters is located in Prague, it trades on the London Stock Exchange. The CMA launched a phase 1 probe into the more than $8 billion cash-plus-stock deal in January and had until March 16 to announce its findings.?
The CMA said that both companies are industry leaders in the cybersecurity field and that a merger could potentially reduce competition in the cyber safety software market of the future.
"Unless the companies can offer a clear-cut solution to address our concerns, we intend to carry out an in-depth phase 2 investigation," said CMA Executive Director David Stewart.
NortonLifeLock and Avast now have five days to submit a proposal to appease those concerns.
However, in response to the investigation, NortonLifeLock was quick to call the CMA's announcement "surprising" and said it doesn't plan to make any phase 1 remedies.
<<<
---
>>> UPDATE 1 - Prologis to buy Duke Realty in $26 bln deal
Reuters
June 13, 2022
https://finance.yahoo.com/news/1-prologis-buy-duke-realty-121523824.html
June 13 (Reuters) - Warehouse provider Prologis Inc said on Monday it would acquire smaller peer Duke Realty Corp in an all-stock deal valued at about $26 billion, including debt.
Last month, Duke Realty had rejected a $23.7 billion all-stock offer from Prologis, calling the offer "insufficient".
Both companies' boards have approved the deal, Prologis said on Monday.
Storage space requirement, especially from e-commerce firms including Amazon, has seen a jump after the pandemic prompted consumers to switch to online shopping.
<<<
---
>>> Nestle Eyed Biggest-Ever Deal in Aborted Move for GSK Unit
Bloomberg
by Aaron Kirchfeld, Ruth David and Dinesh Nair
May 26, 2022
https://finance.yahoo.com/news/nestle-eyed-biggest-ever-deal-165347419.html
(Bloomberg) -- For a fleeting moment, Nestle SA explored what would have been its biggest-ever deal in a move that underscores the consumer giant’s ambition to grow through large acquisitions.
The Swiss company floated the idea in recent months of acquiring GSK Plc’s consumer health arm, people with knowledge of the matter said. It made informal overtures to express interest in the GSK unit around the same time as Unilever Plc’s £50 billion ($63 billion) bid for the business that failed in January, the people said.
As part of its deliberations about a deal, Nestle was considering teaming up with Reckitt Benckiser Group Plc or a similar strategic partner to split up the unit, the people said. However, Nestle quickly dropped its pursuit due to the complexities of a deal and GSK management’s preference for a separate listing of the operations, according to the people.
The revelation comes as GSK pursues one of the largest corporate spinoffs ever attempted in the UK. The unit, now known as Haleon, owns a sprawling portfolio of brands from Advil painkillers to Sensodyne toothpaste. Its plans for a listing come at a time when equity markets globally have been declining amid the war in Ukraine, while new stock offerings have nearly dried up as investors’ risk appetite falls.
Activist Pressure
“Haleon is an attractive consumer asset, which should ultimately be reflected in its independent valuation,” analysts at Jefferies Financial Group Inc. wrote in a note Thursday, citing the potential takeover interest.
The report “suggests” GSK is committed to the spinoff as a tax-free way of crystallizing value for shareholders while also providing £7 billion to pursue pipeline deals, without the potential delays from a sale, according to Jefferies.
Unilever in January abandoned its bid for the GSK business after the UK drugmaker rejected its approaches and it encountered opposition from its own shareholders. GSK Chief Executive Officer Emma Walmsley has consistently argued that the public markets are the best home for Haleon. She’s been seeking to boost performance amid pressure from activist shareholder Elliott Investment Management.
Mega Listing
GSK has made clear it’s keen on creating a large independent firm and achieving long-term growth, compared with the short-term profit from a sale, the people said. Nestle’s interest was seen as an exploratory idea not backed by committed financing, so GSK never had to seriously evaluate it, the people said.
The British company remains focused on the spinoff, and there aren’t any active negotiations between the two parties, the people said. Nestle is still monitoring the situation, and it could revisit its interest depending on how Haleon trades after its stock market debut, they said.
Haleon is in the process of hiring corporate brokers ahead of the planned UK listing, the people said, asking not to be identified discussing confidential information. That move raises the prospect that some large investment banks could switch allegiances in order to represent Haleon, which is expected to immediately become one of the London market’s biggest companies.
Representatives for Nestle, Reckitt and GSK declined to comment.
Portfolio Pruning
Since taking the helm at Nestle in 2017, CEO Mark Schneider has made targeted acquisitions and sold off several underperforming units. Nestle, Europe’s biggest listed company by market value, has been expanding its presence in faster-growing health and wellness products by snapping up firms like nutritional supplement provider Bountiful Co. and hydration-tablet maker Nuun & Co.
Schneider said in February the company was more interested in small and mid-sized deals, though it wouldn’t rule out larger purchases.
Reckitt, the maker of Lysol disinfectants and Durex condoms, has also been revamping its portfolio by offloading businesses seen as less profitable. It has divested its Chinese baby formula unit and has been considering a sale of its remaining infant nutrition operations globally, Bloomberg News reported.
Slough, England-based Reckitt considered buying a portion of Pfizer Inc.’s consumer business in 2018. It eventually backed out of the race, a move applauded by investors at the time.
<<<
---
Neogen - >>> 3M Food Safety Unit and Neogen to Combine in $9.3 Billion Deal
A merger will enable 3M's food-safety unit and Neogen to form a dedicated global food-safety group.
Dec 19, 2021
The Street
https://www.thestreet.com/markets/mergers-acquisitions/3m-food-safety-unit-neogen-combining-in-9point3-billion-deal?puc=yahoo&cm_ven=YAHOO
VERONIKA BONDARENKODEC 14, 2021 3:36 PM EST
Food-safety and animal-health company Neogen (NEOG) - said it would combine with the food-safety branch of 3M (MMM) - Get 3M Company Report, creating a global food-safety and security provider.
The deal is designed to be tax-free to 3M holders. At closing, holders of Neogen, Lansing, Mich., will have 49.9% of the new company and 3M holders receive 50.1%.
3M is the St. Paul, Minn., technology and consumer-products giant, parent to everything from masks and respirators to Post-It notes.
The enterprise value of the combined company is estimated at $9.3 billion.
Both boards have approved the deal. Talks of a merger between the two companies have been in the works and reported on since 2019.
At last check, Neogen shares jumped 8.5% to $43.51 while 3M stock was little changed at $174.50.
The new company will take advantage of a "heightened global focus on food security, sustainability and supply chain solutions," said John Adent, Neogen's chief executive, John Adent, said in a statement. Adent will be leading the new company.
<<<
---
Duke Realty - >>> Warehouse Owner Prologis Offers to Buy Duke Realty for $24 Billion
Bloomberg
by Patrick Clark
May 10, 2022
https://finance.yahoo.com/news/warehouse-owner-prologis-offers-buy-134257618.html
Prologis Proposes To Acquire Duke Realty In All-Stock Transaction Valued At $61.68 Per Share
(Bloomberg) -- Prologis Inc., the giant global warehouse owner, unveiled a roughly $24 billion all-stock offer to acquire Duke Realty Corp., taking its bid public after months of private pushback from the Indianapolis-based real estate investment trust.
The proposal values Duke at $61.68 a share, a 29% premium to its closing price on May 9, according to a letter from Prologis Chief Executive Officer Hamid Moghadam to Duke made public on Tuesday. Duke investors would own 19% of the combined company.
Duke shares were up 10% to $52.46 at 10:52 a.m. in New York. Prologis stock was down 2.9%. A representative for Duke declined comment.
The bid for Duke, which owns about 165 million square feet (15.3 million square meters) of industrial real estate in the US, comes amid a boom in warehouse demand driven by the ongoing shift to e-commerce. The US vacancy rate fell to 3.4% in the first three months of this year even as developers rushed to build new logistics properties, according to Jones Lang LaSalle Inc.
Read more: KKR to Build Warehouses as Demand for Space Outstrips Supply
While Amazon.com Inc. said last month that it had overbuilt its logistics network, landlords see persistent demand for new properties. The tight market for space, meanwhile, is pushing up rents, increasing the logic for mergers.
“The offer reflects that warehouse rent growth has continued to exceed expectations,” Bloomberg Intelligence analyst Lindsay Dutch said in an interview. “M&A gives you quick expansion and exposure to rising rents, compared to the time it takes to build new warehouses.”
If accepted, the Duke proposal would mark a return to dealmaking for Prologis, which acquired DCT Industrial Trust in 2018 and Liberty Property Trust in 2020. Moghadam’s firm has relied on new development to expand its holdings over the past two years, boosting its US portfolio to more than 600 million square feet -- roughly 200 million square feet more than its closest competitor, Blackstone Inc., had at the end of June.
San Francisco-based Prologis cited those deals in its letter and called its track record as an acquirer “incredibly strong,” with recent purchases materially benefiting investors.
Prologis first approached Duke about a potential combination in November, according to the letter. After Duke spurned a series of offers, Moghadam concluded “that a public approach may be more constructive.”
Duke’s industrial holdings are “highly strategic” and “complimentary” to Prologis’s own portfolio of logistics assets, according to the letter. Moghadam said the deal would add to Prologis’s earnings and benefit shareholders of both companies.
What Bloomberg Intelligence Says
“Prologis’ proposal to buy smaller, U.S.-exclusive Duke Realty reignites an acquisition streak that’s been dormant since early 2020 and offers rapid expansion amid strong warehouse rent growth.”
<<<
---
US Ecology acquired - >>> Republic Services and US Ecology Announce Expiration of Hart-Scott-Rodino Waiting Period for the Acquisition of US Ecology
Yahoo Finance
March 31, 2022
https://finance.yahoo.com/news/republic-services-us-ecology-announce-130400466.html
PHOENIX and BOISE, Idaho, March 31, 2022 /PRNewswire/ -- Republic Services, Inc. (NYSE: RSG) and US Ecology, Inc. (NASDAQ-GS: ECOL) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which applies to the proposed acquisition by Republic Services of US Ecology, expired at 11:59 p.m. Eastern Time, on March 30, 2022. The transaction is expected to close during the second quarter, subject to approval by US Ecology's stockholders and satisfaction of the remaining conditions to closing.
About Republic Services
Republic Services, Inc. is a leader in the U.S. environmental services industry. Through its subsidiaries, the Company provides superior service offerings while partnering with customers to create a more sustainable world. For more information, visit RepublicServices.com, or follow us at Facebook.com/RepublicServices, @RepublicService on Twitter or Republic Services on LinkedIn.
About US Ecology
US Ecology is a leading provider of environmental services to commercial and government entities. The company addresses the complex waste management and response needs of its customers offering treatment, disposal, beneficial re-use, and recycling of hazardous, non-hazardous, radioactive and other specialty waste. US Ecology also provides a variety of vertically integrated field services including logistics and response at its customers in-field locations and through its network of 10-day transfer facilities. Logistics solutions include specialty waste packaging, collection lab pack, transportation, and total waste management. Response solutions include emergency response, oil spill response standby services, spill clean-up services, remediation, and industrial services. US Ecology's focus on safety, environmental compliance, and best-in-class customer service enables us to effectively meet the needs of US Ecology's customers and to build long lasting relationships. US Ecology has been protecting the environment since 1952.
<<<
__
>>> REIT Net Acquisitions Hit Record High Of $67.8 Billion In 2021
Forbes
by Calvin Schnure
Mar 9, 2022
https://www.forbes.com/sites/calvinschnure/2022/03/09/reit-net-acquisitions-hit-record-high-of-678-billion-in-2021/?sh=519154a65c03
REITs have been on a buying spree, making $67.8 billion of net acquisitions in 2021. Several factors have contributed to these purchases, including a robust recovery in underlying property markets and solid outlook for future growth, a low cost of capital, and strong balance sheets that are in a good position to support this expansion of their real estate portfolios. And while the war in Ukraine has injected new risks and uncertainties into the outlook, the factors that supported REIT acquisitions last year leave them well-prepared for the path ahead. (Full disclosure, I am Senior Economist and SVP Research Analysis at Nareit, the worldwide representative voice for REITs and listed real estate.)
REIT net property purchases rose steadily through the year last year.
As publicly listed companies, REITs often issue common stock to raise capital to fund their acquisitions. High and rising share prices decrease REITs’ cost of capital, and also generally signal market confidence in the future prospects for income-producing real estate. The 41.3% total stock market return by REITs in 2021 provided both a strong signal to expand and also low-cost access to the capital required to do so. Indeed, REITs raised a record $126.9 billion in 2021 through issuance of common equity, preferred equity, and unsecured debt.
REIT acquisition activity increased steadily through the year, to $26.7 billion in the fourth quarter. Activity was broad-based, with nine of the 12 property sectors having positive net purchase activity, according to the Nareit T-Tracker®. Self storage REITs and residential REITs led the way, with $7.0 billion and $6.2 billion net purchases, respectively. These property sectors have been red-hot during the pandemic. Other sectors with significant net acquisitions include retail REITs and health care REITs, with $5.5 billion and $2.8 billion, respectively. These sectors came under pressure in the early phases of the pandemic, causing disruptions that led to opportunities for repositioning and consolidation.
Self storage, Residential, Retail, Health care and Industrial REITs had major purchases
Nine of the 12 REIT property sectors bought properties, on net
These acquisitions come at a time when REIT operating performance and financial performance are both on the upswing. Occupancy rates of all properties held by REITs rose to 92.3%, an increase of 325 basis points from the low point reached early in the pandemic, and have nearly returned to their levels preceding the pandemic. Across property sectors, occupancy has risen among the apartment, industrial, and retail REIT sectors, while occupancy rates have continued to decline in the office sector.
Occupancy rates reached bottom in mid-2020, but since then have risen for most sectors
Occupancy rates of REIT-owned properties are up 325 basis points from pandemic lows
Financial performance has benefited as conditions in property markets have firmed and occupancy recovers. Indeed, after having declined in 2020, earnings of the REIT sector (as measured by funds from operations (FFO)) rose 24.6% in 2021 to a record high of $64.8 billion.
REITs have strengthened their balance sheets over the past decade, reducing their leverage and locking in low interest rates for well into the future. This solid financial position has not only facilitated the recent wave of acquisitions, but has also reduced exposures to possible increases in interest rates or other shocks in financial markets in the months and years ahead.
<<<
>>> Cybersecurity Stocks To Buy And Watch: Demand Grows For Next-Gen Security
Investor's Business Daily
by REINHARDT KRAUSE
12/28/2021
https://www.investors.com/news/technology/cybersecurity-stocks/?src=A00220
You may think the time is right to move into cybersecurity stocks, if you're reading this IBD investing primer. The IBD Computer-Software Security group ranks No. 20 out of 197 industry groups tracked
The recently disclosed Log4j computer server software vulnerability has spurred a new wave of hacker attacks.
Some cybersecurity stocks, such as CrowdStrike Holdings (CRWD), have pulled back after strong runs.
Ransomware remains a big threat, though fewer highly publicized incidents occurred in the back half of 2021.
The rise of cryptocurrency Bitcoin has been linked to a spike in ransomware attacks. In ransomware attacks, hackers take over computer systems, encrypt files and demand digital payment to restore access to critical data.
Cybersecurity spending worldwide will pop an estimated 13% in 2021 to $172 billion, says market research firm Gartner, accelerating from 8% growth in 2020. In both 2022 and 2023, Gartner forecasts 11% growth in cybersecurity spending.
The financial services industry is a big spender, said Wells Fargo analyst Mike Mayo in a recent report.
"The biggest banks spend as much as $1 billion, or an estimated 10% to 20% of their IT budgets on cyber," said Mayo. He added: "Cyber spending should increase 10% (compound annual growth rate) over the next four years. As banks increasingly rely on digital interactions with customers, the importance of cybersecurity grows."
Cybersecurity Stocks With High Composite Ratings
Fortinet (FTNT) stock, Mimecast (MIME), Zscaler (ZS), Qualys (QLYS) and Palo Alto Networks (PANW) are among cybersecurity stocks with Composite Ratings above 90. FTNT stock was featured in the New America section.
The Composite Rating is a blend of the other five IBD stock ratings: the earnings per share or EPS Rating, Relative Price Strength Rating, Accumulation/Distribution Rating, Industry Group Relative Strength Rating and the SMR Rating.
The latter measures sales growth, profit margins and return on equity. The all-encompassing Composite Rating helps investors easily measure the quality of a stock's fundamental and technical metrics.
No cybersecurity stocks currently are members of the IBD Leaderboard. It's IBD's curated list of leading stocks that stand out on technical and fundamental metrics.
Both CrowdStrike and Zscaler stock have dropped off the IBD 50 roster of growth companies.
Congress has finally passed legislation funding infrastructure projects. The legislation is expected to include funding for federal, state and local cybersecurity infrastructure.
Hot Cybersecurity Startups Eye IPOs
Private equity firms continue to eye cybersecurity stocks. Permira in December agreed to buy Mimecast (MIME) for $5.8 billion. Thoma Bravo in April agreed to buy Proofpoint in an all-cash $12.3 billion deal.
SentinelOne (S)'s initial public offering raised $1.2 billion. SentinelOne is a rival of CrowdStrike in an emerging market.
Meanwhile, analysts say Netskope, Illumio and Menlo Security are among cloud security startups that could launch IPOs. Netskope in early July raised $300 million at a valuation of $7.5 billion.
Analysts say a new wave of startups seems to be taking share from industry incumbents. They include Cybereason, Exabeam, Vectra AI and iBoss.
"Illumio just completed a Series F round for $225 million of 100% primary capital led by Thoma Bravo, where Illumio now sports a $2.75 billion post-round valuation," said Needham analyst Alex Henderson in a report.
Darktrace (DARK) launched its IPO on the London stock exchange in April. Darktrace utilizes self-learning artificial intelligence tools in security automation.
Consolidation may be coming in the cybersecurity industry. Okta in early March acquired privately held Auth0 in a $6.5 billion, all-stock deal. Also, Okta (OKTA) is expanding into new security markets to take on CyberArk Software (CYBR) and SailPoint Technologies (SAIL).
Microsoft Stock A Big Player In Cybersecurity
Also, Microsoft (MSFT) disclosed that its cybersecurity revenues top $10 billion annually. With 400,000 customers, Microsoft's computer security franchise is growing at more than 40%, the company said.
Microsoft in July acquired RiskIQ, a security threat management company. Bloomberg reported that Microsoft paid around $500 million. Microsoft also bought CloudKnox Security in July.
In addition, Microsoft is integrating more security tools into its cloud-based Office 365 software. As it expands cloud-based security services, Microsoft could pressure more industry incumbents, such as Okta, CrowdStrike, and Splunk (SPLK).
"Microsoft is clearly pitching itself as offering a full security suite, a competitive advantage as customers increasingly want a unified view of threats," UBS analyst Karl Keirstead said in a recent note to clients.
Also, one key IBD technical measure for cybersecurity stocks are Relative Strength Ratings. Further, it behooves an investor to know which cybersecurity stocks address ransomware, phishing or other kinds of cyberattacks.
Palo Alto Networks has spent over $3 billion making 10 acquisitions over the past three years. With roots in the "firewall" network security market, Palo Alto aims to build a broad cloud-based security platform.
Further, CrowdStrike uses machine learning and a specialized database to detect malware on laptops, mobile phones and other devices that access corporate networks. In addition, many software companies are using artificial intelligence to get a competitive edge.
In addition, Zscaler is the biggest provider of cloud-based web security gateways that inspect customers' data traffic for malware.
SailPoint, an identity management software maker, is among companies that garner more than 10% of revenue from government agencies.
Coronavirus Outbreak Boosted Demand For Cloud Security
Other cybersecurity firms with a sizable government business include Tenable Holdings (TENB), Rapid7 (RPD) and CyberArk. Tenable in February acquired France-based Alsid, which focuses on identity access management.
Rapid7 and Qualys specialize in vulnerability management services.
Amid the rapid global spread of the coronavirus called Covid-19, many companies instructed employees to work from home. That has increased demand for computer security products that support remote work.
The coronavirus emergency and shift to remote work has accelerated the growth of cloud-based network security. So the industry now has a new term for the infrastructure that supports distributed workers and branch offices.
It's spelled SASE — pronounced "sassy" — and it stands for Secure Access Service Edge.
Cybersecurity Stocks: Remote Work Increases Amid Pandemic
As remote workers access company data via the internet, many businesses are setting up virtual private networks, or VPNs. Some are buying laptops with preinstalled security software.
"We believe corporations are facing challenges in terms of VPN capacity, and protecting workers adequately with next-generation network and endpoint security offerings," William Blair analyst Jonathan Ho said in a report to clients.
He added that "intensifying email and phishing campaigns, identity access management, and control over software applications" are other security issues.
However, industries hard hit by the coronavirus pandemic will spend less on security software. They include airlines, hotels, retail and restaurants.
Meanwhile, one view is that mergers and acquisitions will pick up.
"The cloud has disrupted everything, which presents both threat and opportunity," Jefferies analyst Brent Thill said in a recent note. "The cyber market is riper than ever for ongoing consolidation. Many smaller vendors are attempting to solve the same problems, larger vendors are looking to create security suites, and financing rates are at all-time lows."
Zscaler, Qualys and Ping Identity Holdings (PING) were each featured recently as the IBD Stock of the Day.
In addition, while cybersecurity stocks often get a boost from well-publicized cyberattacks, the impact can be short-lived.
SD-WAN Technology Changes Security Needs
Corporate America has hiked tech spending on security aiming to protect intellectual property as well as consumer privacy. Hackers continue to steal credit card data and intellectual property.
Spending on security technologies has evolved as companies shift business workloads to cloud computing service providers. Amazon Web Services, part of Amazon.com (AMZN), is the biggest cloud services firm. Amazon looms as a potential rival as it builds more security tools into its cloud services.
Also, Fortinet competes with Palo Alto Networks and others in the firewall security market. Firewalls reside between private networks and the internet. They block unauthorized traffic and check web applications for malware.
As large companies shift to off-premise cloud computing services, one view is that firewall technology will play a lesser role. Fortinet has targeted software-defined wide area networks, or SD-WANs, an emerging computer networking technology.
Aiming to catch-up in SD-WAN technology, Palo Alto Networks acquired startup CloudGenix.
Cybersecurity Products Battle Ransomware, Phishing
Cybersecurity stocks span a wide-range of products and services. In addition, some security vendors are shifting to software-based subscription business models from selling hardware appliances.
Proofpoint specializes in email and data-loss protection.
Hackers often aim to compromise networks by targeting employees or management who have administrative access. CyberArk manages privileged accounts. In addition, Okta provides identity management services.
To slow down hackers, more companies are focusing on internal security threats though a strategy known as Zero Trust.
In addition, traditional security measures aim to keep the bad guys out of corporate networks. Further, network firewalls focus on intruders from the public internet.
Zero Trust cybersecurity models focus on internal threats, such as hackers stealing someone's security credentials. Security firms verify the identity of network users and limit access to applications.
CrowdStrike, Okta, Netskope and Proofpoint recently formed a Zero Trust alliance.
Targeting Zero Trust security, Cisco Systems (CSCO) in 2018 acquired Duo Security for $2.35 billion.
Artificial Intelligence Changing Cybersecurity Market
Also, many fast-growing cybersecurity firms are in the endpoint market. Their tools detect malware on laptops, mobile phones and other devices that access corporate networks.
Further, CrowdStrike's initial public offering in June, 2019 raised $612 million, one of the largest cybersecurity offerings. CrowdStrike's rivals include VMware's (VMW) Carbon Black, Palo Alto, FireEye (FEYE) and startup Cybereason. Private equity firms Blackstone and ClearSky recently invested $400 million in FireEye.
In addition, state-sponsored hackers and cybersecurity firms are both using artificial intelligence to get an edge.
Artificial intelligence should improve computer security tools by speeding up incident responses. It could help thwart email-delivered ransomware or swarming botnets that knock out access to websites.
Follow Reinhardt Krause on Twitter @reinhardtk_tech for updates on 5G wireless, artificial intelligence, cybersecurity and cloud computing.
<<<
>>> American Tower (AMT) Announces Deal to Buy CoreSite for $10.1B
Zacks Equity Research
November 16, 2021
https://finance.yahoo.com/news/american-tower-amt-announces-deal-135801583.html
American Tower Corporation AMT has entered into a definitive agreement to acquire CoreSite Realty Corporation COR for roughly $10.1 billion. The combined company will cater to the growing need for convergence between mobile network providers, cloud service providers, and other digital platforms amid accelerating global 5G deployments.
The data center management company, CoreSite, consists of 25 data centers, 21 cloud on-ramps and more than 32,000 interconnections in eight major U.S. markets. As of Sep 30, 2021, CoreSite generated annualized revenues and adjusted EBITDA of $655 million and $343 million, respectively. Hence, the property buyout is likely to increase American Tower’s scale.
Moreover, with the addition of CoreSite’s data and cloud management capabilities to its mobile edge compute business American Tower will be able to offer a huge variety of 5G and cloud solutions.
Per management, “We expect the combination of our leading global distributed real estate portfolio and CoreSite’s high quality, interconnection-focused data center business to help position American Tower to lead in the 5G world.”
The transaction, expected to close by the end of this year, will likely be accretive to American Tower’s adjusted funds from operations (AFFO) per share and be increasingly accretive over time.
This marks American Tower’s second acquisition deal this year. Previously, AMT agreed to acquire Telxius Towers for $9.4 billion in cash in January. In June, it closed the first tranche of this previously announced acquisition, which comprised roughly 20,000 communications sites in Germany and Spain.
Shares of this Zacks Rank #3 (Hold) company have appreciated 5.9% compared with its industry's 10.9% growth, in the past six months. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
However, tenant concentration is very high for American Tower. In fact, of its top three customers, Verizon VZ and AT&T T accounted for majority of the company’s total revenues.
Hence, loss of either Verizon or AT&T, consolidation among them, or reduction in network spending will significantly hamper American Tower’s top line.
<<<
>>> Biden's antitrust crackdown adds to anxiety of merger investors
Reuters
By Anirban Sen
https://www.reuters.com/business/bidens-antitrust-crackdown-adds-anxiety-merger-investors-2021-08-05/
Aug 5 (Reuters) - U.S. President Joe Biden's tougher regulatory stance on big corporate mergers has fueled a rise in investor bets on some deals not being completed, threatening to push the brakes on a record-setting dealmaking boom.
Spreads between deal prices and the share prices of acquisition targets widened this week after the U.S. Federal Trade Commission said on Tuesday that a surge in mergers and acquisitions (M&A) would delay antitrust reviews, and that companies that did not wait for their outcome completed their deals at their own risk.
On Wednesday, the Information reported that the U.S. Department of Justice was weighing a lawsuit to block UnitedHealth Group's (UNH.N) nearly $8 billion deal to acquire health care analytics and technology vendor Change Healthcare (CHNG.O). Such a move would follow its lawsuit to block Aon's (AON.N) $30 billion acquisition of Willis Towers Watson (WTY.F), which resulted in the insurance brokerages abandoning their deal last month.
"The fact that spreads have widened is the understatement of the year," said Roy Behren, managing member of Westchester Capital Management, which currently has $5.1 billion of assets under management, 85% of which is invested in merger arbitrage.
The White House did not immediately respond to a request for a comment.
Widened spreads include the proposed $33.6 billion deal between railroad operators Canadian National Railway (CNR.TO) and Kansas City Southern (KSU.N), as both companies await approval from the Surface Transportation Board. Shares of Kansas City are currently trading at $262 apiece, well below the agreed cash-and-stock deal of $325 per share.
Zoom Video Communications' (ZM.O) nearly $15 billion all-stock deal for cloud-based call center operator Five9 Inc (FIVN.O) and medical device maker Thermo Fisher's (TMO.N) $17.4 billion buyout of contract researcher PPD Inc (PPD.O).
Adding to the anxiety of merger investors are the escalating geopolitical tensions between China and the United States. China can thwart mergers of U.S. companies if they have a significant presence in the country.
The spread on semiconductor designer Advanced Micro Devices Inc's (AMD.O) $35 billion acquisition of Xilinx Inc (XLNX.O) has widened in recent days for that reason, investors said.
"The climate of fear surrounding transactions that require Chinese approval is as difficult as I've seen in many, many years," said Behren.
It is not uncommon for M&A spreads to widen in times of uncertainty. They blew up dramatically in March 2020, when Wall Street fretted over the financial fallout of the coronavirus outbreak.
<<<
>>> What Microsoft’s Nuance Acquisition Means for the Healthcare Industry
The purchase gives the tech giant access to advanced speech recognition and artificial intelligence technology and expands its presence within the healthcare space.
HealthTech
by Mike Larsen
https://healthtechmagazine.net/article/2021/07/what-microsofts-nuance-acquisition-means-healthcare-industry
Microsoft agreed to acquire speech recognition and artificial intelligence company Nuance Communications for $19.7 billion in April. The acquisition establishes Microsoft as a major player in healthcare technology by bridging the gap between clinicians and Microsoft Cloud for Healthcare.
The tech giant launched Cloud for Healthcare late in 2020. It includes healthcare-specific versions of Microsoft 365, Azure, Dynamics 365 and Power Platform. Additional features include streamlined appointment scheduling, integration with electronic health records and collaboration on a secure platform. Although Microsoft hinted at direct patient care capabilities, this wasn’t confirmed until the Nuance announcement.
Nuance has been a healthcare industry powerhouse for years, based on its market share in speech recognition, artificial intelligence and natural language processing. Clearly, Microsoft saw an opportunity to leverage Nuance’s intellectual property, which has broad utility within healthcare and other industry verticals.
patient-centered care
What Can Nuance’s Speech Recognition Technology Do?
Nuance released Dragon NaturallySpeaking in 1997, and it wasn’t long before the medical community took notice. Clinicians in particular stood to benefit from the use of front-end speech recognition and reduced need for transcription services. Over the years, the technology has evolved to include the ability to learn medical terminology, languages and accents.
In recent years, Nuance applied AI to its software for new use cases, including ambient clinical documentation. In this case, a smart speaker in an exam room picks up on key words during a patient visit and can translate the relevant speech into actions or activities within the EHR. For example, a physician could use a voice command to order medications or add a diagnosis to the chart.
Ambient clinical documentation and other new advances in technology inevitably raise questions of security and privacy. Nuance solutions maintain the highest levels of HIPAA compliance, as all protected health information and personally identifiable information is encrypted at use, in transit and at rest. Features such as ambient listening can be toggled off if more privacy is needed.
DIVE DEEPER: How can healthcare leverage natural language processing for medical records?
What’s Next for Speech Recognition in Healthcare?
Microsoft’s acquisition is certain to accelerate the use of AI and natural language processing within clinical workflows. For example, NLP allows providers to gather data from the point of care for comparison with large data sets within the EHR or Microsoft Cloud for Healthcare. This approach enables clinical decision support in real time, leading to better outcomes and patient satisfaction.
Demand for speech recognition continues to be high, and the combination of Nuance’s intellectual property and Microsoft’s cloud and analytics capabilities will result in more sophisticated offerings with increased interoperability. In addition, Microsoft can apply the technology to other industries and use cases, which could lead to more development within speech recognition and AI.
<<<
>>> Biggest M&A deals in 2020
Dealroom.net
by Kison Patel
CEO and Founder of DealRoom & M&A Science
https://dealroom.net/blog/notable-mergers-and-acquisitions-deals
US$30 billion acquisition of Willis Towers Watson by AON
US$21 billion acquisition of Maxim Integrated by Analog Devices
US$21 billion acquisition of Speedway gas stations by Seven and I
US$18.5 billion acquisition of Livongo by Teladoc
US$13 billion acquisition of E*Trade by Morgan Stanley
US$7.3 billion acquisition of GrubHub by Just Eat
US$6 billion acquisition of Credit Karma by Intuit
1. US$30 billion acquisition of Willis Towers Watson by AON
In the future, risk assessors may look back at 2020 as the year which defined the term, ‘black swan event’. But the year will also be notable for a different reason: the US$30 billion of Willis Towers Watson by AON - the insurance industry’s largest ever acquisition.
The combination, which should be confirmed in the first quarter of 2021, comes at a time when the insurance industry faces a range of new threats ranging from coronavirus in the short-term to climate change and cyber security in the long-term.
The all-stock deal makes AON (which the merged company will be called) the largest insurance broker in the world.
2. US$21 billion acquisition of Maxim Integrated by Analog Devices
Analog Devices is one of those companies that not everybody will have heard of, but one that they will all have come into contact with on a daily basis.
As the world’s largest manufacturer of semiconductors, Analog (as it’s more commonly referred to) produces the chips and electronics that power some of the most well-known products in the healthcare, automotive, industrial and consumer segments.
Its acquisition of Analog Devices - another all-share deal, reflecting the ongoing pandemic environment in which companies are hoarding cash - strengthens its position as the number one in its industry.
And with both companies specializing in different industries, the deal is expected to yield synergies of close to US$300 million.
3. US$21 billion acquisition of Speedway gas stations by Seven and I
During a year which has seen most people work at least a few months from home, reducing the need for transport, the idea of two gas station giants merging may seem like a strange one.
Seven and I, the Japanese owner of the ubiquitous 7-Eleven convenience stores, begged to differ: it says the acquisition of Marathon Petroleum’s Speedway gas stations allows it to tap into US economic and population growth at a time when Japan’s economy and population are moving in the opposite direction.
The deal also means that Seven and I will control more than 14,000 gas and convenience stores in North America.
The marketing segment of the oil and gas industry has traditionally been one of the most resilient, so don’t be surprised to see more consolidation of gas stations in the not-too-distant future.
4. US$18.5 billion acquisition of Livongo by Teladoc
Very few industries have managed to completely avoid the carnage wrought by the coronavirus pandemic. One such industry, which has not only managed to avoid the carnage, but thrive, is the telehealth industry.
The pandemic created a surge in demand for the services offered by companies like Livongo and Teladoc. Before the deal, each company was separately valued at US$8.5 billion, but the cash and stock deal creates a company valued post-transaction at US$18.5 billion.
Critics of the deal suggest that Teladoc has overpaid for Livongo and there may be big integration issues ahead for the two companies.
But those behind the deal are hoping that the new users of both services added during the pandemic represent a long-term shift in patient behaviour rather than just a short-time boost to revenue.
5. US$13 billion acquisition of E*Trade by Morgan Stanley
February 2020 seems like a long time ago for most people, given what has happened in the interim.
But cast your mind back and you may recall that February was the month in which investment bank Morgan Stanley acquired the world’s most popular online trading platform, E*Trade.
Retail investors are increasingly investing from their desktops, turning away from the traditional broker-dealer paradigm, so the deal was an obvious move by Morgan Stanley to gain a foothold in that market.
With approximately US$360 billion of retail client assets, the acquisition of E*Trade increases Morgan Stanley’s AUM by over 10%. And perhaps even more importantly, the deal nearly triples Morgan Staley’s client database from 3 million to 8.2 million.
6. US$7.3 billion acquisition of GrubHub by Just Eat
Up until Just Eat announced that it had acquired GrubHub in June 2020, it looked as though Uber was going to acquire America’s most popular food delivery company.
The last minute swoop by Just Eat means the company now has a large footprint in over 13 different countries and becomes the world’s largest food delivery company.
At the time of the acquisition, Just Eat announced that GrubHub had over 300,000 restaurants spread across 4,000 US cities. Although the deal creates a dominant name in food delivery, it’s difficult to see what the benefit from scale is for Just Eat.
Furthermore, 2020 was marked by strikes by gigging couriers across the world suggesting choppy waters ahead for the food delivery industry and possibly the gig industry as a whole.
7. US$6 billion acquisition of Credit Karma by Intuit
Intuit may be better known to most as the financial platform company behind popular software programs such as Turbo Tax, QuickBooks and Mint.
Although Intuit has a long history of acquisitions, this latest, all-cash transaction with Credit Karma, is the biggest by some distance.
From the outside, the deal looks like a winner. Intuit can add Credit Karma’s popular credit rating tools to its bundle to offer its clients a complete suit of personal finance tools.
Not to mention the fact that the deal creates a highly complementary dataset: What could make Credit Karma’s credit scores even more accurate? Direct access to people’s financials and tax returns.
<<<
>>> Biggest M&A Deals from 2021
Dealroom.net
by Kison Patel
CEO and Founder of DealRoom & M&A Science
https://dealroom.net/blog/notable-mergers-and-acquisitions-deals
If 2020 was the year that showed that M&A activity is highly resilient to almost any economic setbacks, 2021 proves that it will always rebound to new levels after recovering from those setbacks.
This year is only a little over six months in, and already three of those months have set new records for global M&A activity.
This surge in activity is likely to be repeated for the many M&A practitioners that use DealRoom for its M&A deal management services.
Below, we look at some of the biggest deals of 2021 (so far) and past from 2020, all of which we feel are likely to have significant implications for their respective industries in the years ahead.
Biggest M&A deals in 2021
US$30 billion acquisition of KCS by Canadian National Railway
US26 billion acquisition of Shaw Communication by Rogers Communication
US$22 billion acquisition of Deutsche Wohnen by Vonovia
US20 billion acquisition of Nuance Corporation by Microsoft
US17.4 billion acquisition of PPD by Thermo Fisher Scientific Inc.
US8 billion acquisition of William Grace by Humana
US8 billion acquisition of MGM Studios by Amazon
1. US$30 billion acquisition of KCS by Canadian National Railway
The biggest M&A deal of the year may end up not being a deal at all if the antitrust legislators decide that this transaction works against competition in the United States.
The more you read about the CEO of CN talking up how the deal generates competition, the more you begin to think it’s a case for antitrust.
The combined firm would bring an integrated logistics firm that spans Canada, the United States, and Mexico, potentially perfectly timed for reset trade relations between the US and Mexico.
2. US26 billion acquisition of Shaw Communication by Rogers Communication
On the subject of monopolies…
The acquisition of Shaw Communication by Rogers creates a national behemoth in Canadian mobile communications.
Perhaps as a sop to regulators, the combined company has already committed to investing $2.5 billion in 5G infrastructure across Western Canada over the next half decade.
On the other side, it has also seen plenty of opposition from consumer groups, who allege (with some justification) that it pangs of a bad deal for Canadian telecoms consumers.
3. US$22 billion acquisition of Deutsche Wohnen by Vonovia
Maybe 2021 will be seen as the year of the anti monopoly regulators waving a white flag. In May, the largest residential property group in Germany made a play for the second largest.
The deal is still the biggest so far this year in Europe. When combined, the new firm will control more than 500,000 properties.
Vonovia had been eyeing up a takeover of its rival for several years and had previously had two offers rejected. Third time appears lucky, depending on what Germany regulators make of the deal.
4. US20 billion acquisition of Nuance Corporation by Microsoft
Microsoft’s $20 billion acquisition of Nuance Corporation gives it a large footprint in healthcare.
According to details of the deal released by Microsoft, the target company’s solutions are used by more than 55% of physicians, and 75% of radiologists in the US, and used in 77% of US hospitals.
It therefore represents an excellent acquisition for Microsoft Cloud for Healthcare, introduced in 2020, and Microsoft’s attempt to bring its industry-specific cloud strategy to the healthcare sector. It paid a 23% premium on the Nuance share price.
5. US17.4 billion acquisition of PPD by Thermo Fisher Scientific Inc.
This deal brings together a leader in scientific instrumentation, reagents and consumables, and software and services (Thermo Fisher Scientific) with a leader in clinical research services (PPD).
The deal is expected to generate in the region of $125 million in synergies. It also gives Thermo Fisher Scientific Industries a foothold in the $50 billion clinical research industry.
The acquisition should allow the company to provide a fuller range of services to its clients in areas such as pharmaceuticals and life sciences. It paid a 24% premium on the PPD share price.
6. US8 billion acquisition of William Grace by Humana
Humana already owned 40% of William Grace through its acquisition of the company in partnership with private equity firms TPG Capital and WCS in 2018. This deal represents its buying out of the remaining 60% of the shares of William Grace.
It will also see the new company rebranding as “CenterWell Home Health,” an extension of its payer-agnostic health care services brand, CenterWell. At this stage, it looks as though the big winners from this deal may be TPG Capital and WCS.
7. US8 billion acquisition of MGM Studios by Amazon
It’s never easy to pin down Amazon’s acquisition strategy. Between acquisitions of the Washington Post one minute, and Whole Foods the next, mixed with some acquisitions in drone companies along the way, it’s fair to say it’s a mixed bag.
The 2021 acquisition of MGM Studios looks like it could be a play for Amazon Prime Content - allowing the company to generate spin offs of its existing titles.
These include the franchises for James Bond and Rocky, both potentially highly lucrative on their own. Like several other deals on this list, however, the deal still requires government approval, so it’s unclear whether it will ever close.
<<<
>>> Brooks Automation To Acquire Precise Automation For $70M
Yahoo Finance
by Anusuya Lahiri
April 26, 2021
https://finance.yahoo.com/news/brooks-automation-acquire-precise-automation-124219327.html
Brooks Automation Inc (NASDAQ: BRKS) has inked an agreement to acquire collaborative robots and automation subsystems developer Precise Automation for $70 million.
Precise’s technology enables convenient human-robot workflows via process automation.
Precise’s products are used in laboratory automation and semiconductor and electronics manufacturing end-markets.
Precise’s history of innovation in vision technology, precision motion, integrated controllers and direct-drive motors, and track record of solving customer challenges in laboratory and semiconductor automation made it a great fit with Brooks, Brooks CEO, Steve Schwartz said.
Precise co-founders Brian Carlisle and Dr. Bruce Shimano will join Brooks. Precise produced $17 million in revenue over the last year.
Brooks expected the acquisition to be immediately earnings accretive. It held $323 million in cash and equivalents as of Dec. 31, 2020.
Price action: BRKS shares traded higher by 3% at $105.82 in the premarket session on the last check Monday.
<<<
>>> Canadian Pacific to buy Kansas City Southern in $25 billion railway bet on trade
Yahoo Finance
Nandakumar D, Ann Maria Shibu and Rebecca Spalding
March 20, 2021
https://finance.yahoo.com/news/canadian-pacific-buy-kansas-city-034255096.html
Canadian Pacific to buy Kansas City Southern in $25 billion railway bet on trade
(Reuters) - Canadian Pacific Railway Ltd agreed on Sunday to acquire Kansas City Southern in a $25 billion cash-and-stock deal to create the first railway spanning the United States, Mexico and Canada, standing to benefit from a pick-up in trade.
It would be the largest ever combination of North American railways by transaction value. It comes amid a recovery in supply chains that were disrupted by the COVID-19 pandemic, and follows the ratification of the US-Mexico-Canada Agreement (USMCA) last year that removed the threat of trade tensions that had escalated under former U.S. President Donald Trump.
"Think about what we've gone through, think about the importance in North America of near-shoring that is occurring. This network uniquely provides a supply chain that allows our customers and our partners to actually benefit from that and leverage that opportunity," Canadian Pacific Chief Executive Keith Creel told Reuters in an interview.
The combination needs the approval of the U.S. Surface Transportation Board (STB). The companies expressed confidence this would happen by the middle of 2022, given that the deal would unite the smallest of the seven so-called Class I railways in the United States, which meet in Kansas City and have no overlap in their routes. The combined railway would still be smaller than the remaining five Class I railways.
The STB updated its merger regulations in 2001 to introduce a requirement that Class I railways have to show a deal is in the public interest. Yet it provided an exemption to Kansas City Southern given its small size, potentially limiting the scrutiny that its acquisition will be subjected to.
"I don't see it as the kind of consolidation that should raise concerns because it's what you call an end-to-end or vertical merger. Their networks fit nicely with each other and help fill out North America with real service," said economist Clifford Winston, a senior fellow at the Brookings Institution who specializes in the transportation sector.
An STB spokesman said the regulator had not yet received a filing from the companies, which would start its formal review process. He declined to comment further.
Still, Canadian Pacific agreed in its negotiations with Kansas City Southern to bear most of the risk of the deal not going through. It will buy Kansas City Southern shares and place them in an independent voting trust, insulating the acquisition target from its control until the STB clears the deal.
Were the STB to reject the combination, Canadian Pacific would have to sell the shares of Kansas City Southern, and one source close to the agreement suggested they could be divested to private equity firms or be relisted in the stock market. Kansas City Southern shareholders would keep their proceeds.
There is a $1 billion reverse breakup fee that Canadian Pacific would have to pay Kansas City Southern if it cannot complete the formation of the trust, the source added.
Shareholders of Kansas City Southern will receive 0.489 of a Canadian Pacific share and $90 in cash for each Kansas City Southern common share held, valuing Kansas City Southern at $275 per share, a 23% premium to Friday's closing price, the companies said in a joint statement. Including debt, the deal is valued at $29 billion.
Kansas City Southern shareholders are expected to own 25% of Canadian Pacific's outstanding common shares, the companies said. Canadian Pacific said it will issue 44.5 million shares and raise about $8.6 billion in debt to fund the transaction.
It is the top M&A deal announced thus far in 2021. While it is the biggest ever involving two rail companies, it ranks behind Berkshire Hathaway's purchase of BNSF in 2010 for $26.4 billion. For a Factbox on the deal highlights see:
Creel will continue to serve as CEO of the combined company, which will be headquartered in Calgary, the companies said in a statement.
The companies also highlighted the environmental benefits of the deal, saying the new single-line routes that would be created by the combination will help shift trucks off crowded U.S. highways and cut emissions.
Rail is four times more fuel efficient than trucking, and one train can keep more than 300 trucks off public roads and produce 75% less greenhouse gas emissions, the companies said in the statement.
FAILED BIDS
Calgary-based Canadian Pacific is Canada's No. 2 railroad operator, behind Canadian National Railway Co Ltd, with a market value of $50.6 billion.
It owns and operates a transcontinental freight railway in Canada and the United States. Grain haulage is the company's biggest revenue driver, accounting for about 58% of bulk revenue and about 24% of total freight revenue in 2020.
Kansas City Southern has domestic and international rail operations in North America, focused on the north-south freight corridor connecting commercial and industrial markets in the central United States with industrial cities in Mexico.
Canadian Pacific's latest attempt to expand its U.S. business comes after it abandoned a hostile $28.4 billion bid for Norfolk Southern Corp in April 2016. Canadian Pacific's merger negotiations with CSX Corp, which owns a large network across the eastern United States, failed in 2014.
A bid by Canadian National Railway Co, the country's biggest railroad, to buy Warren Buffett-owned Burlington Northern Santa Fe was blocked by U.S. antitrust authorities more than two decades ago.
A private equity consortium led by Blackstone Group Inc and Global Infrastructure Partners (GIP) made an unsuccessful offer to acquire Kansas City Southern last year. The sources said that bid helped revive Canadian Pacific's interest in Kansas City.
BMO Capital Markets and Goldman Sachs & Co. LLC are serving as financial advisors to Canadian Pacific, while BofA Securities and Morgan Stanley & Co. LLC are serving as financial advisors to Kansas City Southern.
<<<
AAWC $$$...DCGD 2.0, PROBABLY BIGGER..MASSIVE MOVE COULD START ANYDAY NOW !!!
>>> Vertiv Is Teaming Up With Honeywell on Data Centers. Its Stock Looks Promising.
Barron's
By Al Root
Oct. 16, 2020
https://www.barrons.com/articles/vertiv-is-parterning-with-honeywell-on-data-centers-its-stock-looks-promising-51602898166?siteid=yhoof2&yptr=yahoo
Honeywell and Vertiv announced a joint effort on Thursday to help data centers reduce energy consumption.
Honeywell International is acting more like a software company than an industrial conglomerate. The company announced a techlike collaboration this past week with another firm that should enhance both partners’ long-term outlooks.
That’s a small bit of good news for Honeywell (HON) investors. But it could be a very big bit of good news for the company Honeywell joined with: Vertiv Holdings (VRT).
Honeywell and Vertiv announced a joint effort on Thursday to help data centers reduce energy consumption. Honeywell’s Building Technologies division provides management systems for data centers that run things such as air conditioning and sprinklers. Vertiv makes power-management systems for data centers.
Power is a big deal for data centers, which consume 1% of the world’s total energy output. Reduced consumption can save big dollars. “Our offerings complement each other to provide greater value to data center operators,” said Vertiv CEO Rob Johnson in the company’s news release.
Data centers were booming even before Covid-19 made the term “work from home” ubiquitous and increased the need for businesses to house and host key processes in the cloud.
The power-management products Vertiv provides are a critical component of a data center. “You can’t just plug a server into the wall,” Vimal Kapur, the CEO of Honeywell Building Technologies, or HBT, tells Barron’s. Data centers require uninterruptible power and sophisticated systems to manage voltage and current. After the servers, power-management systems are a data center’s second biggest expense.
Kapur’s unit, which includes data centers, accounted for about 16% of Honeywell’s total sales in the second quarter of 2020. Data-center products account for a majority of Vertiv’s sales.
Industry analysts, even before Covid, expected data centers to handle about 175 zettabytes of data by 2025, up from about 21 zettabytes by the end of 2021. (Zetta is one with 21 zeros behind it. It’s a big number.)
That’s about 70% average annual growth, yet Vertiv, a key supplier to the industry, trades for only about 16 times estimated 2021 earnings of $1.15 a share, a discount to the roughly 21 price/earnings ratio of the S&P 500 index. Stock in data-center operator Switch (SWCH) trades for about 65 times estimated 2021 earrings.
We aren’t suggesting Vertiv should trade for 65 times earnings. It’s largely an industrial hardware business, which goes through cycles related to IT spending and the health of the overall economy.
Still, the outlook for the company looks bright. And the Honeywell partnership offers another way for Vertiv investors to win: by being bought.
“We see this relationship as…[a] natural extension for HBT into a large and growing addressable market,” wrote Baird analyst Peter Armnet in a Thursday research report. “Longer-term, if the partnership shows success, [Vertiv] could become an attractive fit inside HBT as an acquisition candidate given its growth opportunity, share gain, and margin expansion likelihood as SaaS [software-as-a-service] offerings grow.”
Honeywell has its own software aspirations. It generates roughly 14% of total sales from software solutions. And Vertiv isn’t all about hardware. Its Services unit, which include software products, account for about 30% of sales.
Acquisition timing—and pricing—is hard to predict. Fortunately, Vertiv has another thing going for it. It’s perfect on Wall Street. Eight out of eight analysts covering the company rate shares Buy. The average Buy-rating ratio for stocks in the Dow Jones Industrial Average is about 58%. The average analyst price target for Vertiv stock is about $21 a share, up about 15% from a recent level of $18.34.
Wolfe analyst Nigel Coe calls Vertiv a growth and value story. He sees sales and earnings growing an average 7% and 20% a year, respectively, between 2020 and 2023, driven, in part, by the secular tailwinds in the data-center space. But with a below-average P/E multiple and an opportunity to improve profit margins, he believes value investors should look at Vertiv as well. Coe’s price target is $23, 25% higher than recent levels.
Vertiv reports earnings on Nov 4. Honeywell will report on Oct. 30. Investors can expect to hear more about potential benefits for joint product offerings then. Goldman Sachs analyst Mark Delaney expects Vertiv’s sales growth to be solid but adds “investors should be mindful of historical digestion periods in this end market.” Still, he rates the shares Buy. His price target is $19 a share.
<<<
check out this ticker under one dollar ev company GPVRF /
https://investorshub.advfn.com/GREENPOWER-MOTOR-CO-INC-GPVRF-30416/
https://www.greenpowerbus.com/
might be a good play
rachael
$CURR news on a $20 million acquisition of Sera Labs to secure highly valuable assets in the continuously growing CBD products market.
Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, to be acquired by CURE Pharmaceutical in a $20 Million Transaction
Press Release | 07/30/2020
Privately held Sera Labs, a leading CBD health and wellness company, announced today that it has entered into a Memorandum of Understanding for a 100% acquisition by CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company for a total up-front consideration of $20 million, comprising $19 million in CURE stock at a valuation of $2.75 per share, and $1 million in cash, with an initial, additional commitment of $4 million for working capital in support of accelerating Sera Labs’ growth. The transaction also includes the potential for an earn out of up to $20 million in CURE stock at a valuation of $3.34 per share within two years of the closing of the acquisition, contingent upon Sera Labs achieving certain key financial targets. The structure of the earn out is designed to align risk and reward between CURE stockholders and Sera Labs’ management, with a focus on strong operational alignment and financial execution. The transaction is expected to close, subject to a definitive agreement and customary closing conditions, by the fourth quarter of 2020.
Sera Labs was founded in 2018. Net sales (unaudited) for the most recent quarter ended June 30, 2020, totaled $1.8 million, reflecting a steep sales growth trajectory and early strong reception for its novel products across the CBD-based beauty, health & wellness, and pet product markets. The increase in sales, as projected for the third and fourth quarters and beyond, is subject to this agreement’s new infusion of capital, and attributable to newly signed distribution agreements, the acceptance of additional retailers for CBD, and the explosive growth of Sera Labs’ digital opt-in subscription model, which is just beginning to show rapid growth in line with internal projections.
“Sera Labs has quickly become a standout leader in the CBD industry,” said Nancy Duitch, Sera Labs Founder and CEO. “We attribute our success to capturing a broad distribution network that serves major retailers/distributors and consumers with solution-oriented products and value-driven, trusted brands. The Sera Labs team consists of highly experienced experts who have a track record of creating multiple national brands by utilizing direct-to-consumer marketing to generate recurring revenue. The Sera Labs team has built brands that have generated more than $5 billion in retail sales during the course of their combined careers. We are most excited about the opportunity to vertically integrate with CURE’s domestic cGMP manufacturing and distribution, which will result in a streamlined supply chain. We are confident that with the novel and patented formulation technologies and know-how of CURE, we will be able to accelerate sales growth and achieve consistent profitability much more rapidly than could have been achieved on our own.”
BDS Analytics and Arcview Market Research estimate that the U.S. market for hemp-derived CBD products will exceed $20 billion by 2024.
“CURE’s acquisition of Sera Labs will add a growing brand portfolio and monetization platform that fits remarkably well with CURE’s development capabilities, products, and existing market verticals,” said Rob Davidson, CURE Pharmaceutical CEO. “By integrating Sera Labs’ products and processes with those of CURE’s, and leveraging our cGMP manufacturing facility to realize economies of scale, we will drive improved margins and profitability. This acquisition comes on the heels of our most recent pharmacokinetic study, which showed that our CUREform thin film technology improved cannabidiol bioavailability, and sets the stage for potentially exciting opportunities to apply our innovative dosage forms to Sera Labs’ products. We look forward to joining forces with the Sera Labs team as well as Nancy Duitch’s continued leadership at the helm of Sera Labs and as a key member of CURE‘s leadership team upon closing of the transaction.”
About Sera Labs
Sera Labs is a trusted leader in the health, wellness and beauty sectors of CBD. Sera Labs creates high quality products that use science-backed, proprietary formulations and organic hemp. Its more than 20 products are sold under the brand names SeraRelief™, SeraTopical™, SeraLabs™, Gordon’s Herbals™ and SeraPets™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions.
For more information visit: www.Seralabshealth.com and follow @theseralabs, or contact: press@theseralabs.com
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005347/en/
>>> The Criticized Raytheon-United Technologies Deal Looks Smart Now
The pandemic has slammed the commercial aerospace business, but defense spending remains robust.
Bloomberg
June 8, 2020
https://www.bloomberg.com/news/articles/2020-06-08/raytheon-and-united-technologies-merger-looks-pretty-smart?srnd=premium
Around this time last year, United Technologies Corp. and Raytheon Co. announced their plans to create an aerospace and defense behemoth with about $75 billion in sales. In short order, activist investor Bill Ackman declared he couldn’t “comprehend the strategic logic” of pairing the UTC airplane parts divisions with Raytheon weapons businesses that he deemed “of inferior quality.” Fellow UTC shareholder Dan Loeb followed with his own blast, calling the deal “ill-conceived” and “motivated by empire building.”
Today, shareholders have to be feeling pretty grateful they didn’t listen to Ackman or Loeb and instead approved the all-stock deal that created Raytheon Technologies Corp. earlier this year.
The argument against the merger was that it would turn United Technologies back into a conglomerate just after it had at long last agreed to unwind its sprawling structure through the spinoffs of its Carrier climate control and Otis elevator units. That critique felt off the mark: Sure, jet engines and missiles are different businesses, but the markets are complementary, have similar capital requirements and profit margins, and are followed by many of the same Wall Street analysts. In an interview at last year’s Paris Air Show, Toby O’Brien—now chief financial officer of Raytheon Technologies—cast the deal as a way to make the combined businesses more resilient in the event of a downturn. At the time, the commercial aerospace and defense industries were both seeing robust growth. But it’s rare for the two to move in tandem, and eventually that dynamic would end, O’Brien said.
And end it did. While no one could have predicted the coronavirus pandemic, the merger’s benefits are more apparent than ever. In comparison with a commercial aerospace sector that’s been rocked by a precipitous drop-off in air travel, the legacy Raytheon defense businesses have remained healthy as cash continues to flow from governments committed to supporting critical infrastructure investments. “We generally see the year playing out consistent with how we saw it at the beginning of the year,” O’Brien said of the defense divisions on June 2 at a UBS Group AG conference. How many other businesses can say they’re still more or less where they expected to be in January?
That’s an asset for Raytheon’s financials: The defense businesses should generate about $3.5 billion of free cash flow this year, O’Brien said, helping offset what’s expected to be a break-even performance from the legacy UTC aerospace units. But it also helps the company’s workforce. Whereas rival General Electric Co. is cutting about 25% of its aviation unit employees, Raytheon has so far managed to avoid mass layoffs, in part because it can reallocate workers to its healthier defense businesses.
<<<
>>> AstraZeneca Approaches Gilead About Potential Merger
Bloomberg
By Ed Hammond, Aaron Kirchfeld, and Dinesh Nair
June 7, 2020
https://www.bloomberg.com/news/articles/2020-06-07/astrazeneca-is-said-to-approach-gilead-about-potential-merger?srnd=premium
U.K. drugmaker contacted Gilead last month; no formal talks
Deal with $96 billion U.S. firm would be record in health care
AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record.
The U.K.-based firm informally contacted Gilead last month to gauge its interest in a possible tie-up, the people said, asking not to be identified because the details are private. AstraZeneca didn’t specify terms for any transaction, they said. While Gilead has discussed the idea with advisers, no decisions have been made on how to proceed and the companies aren’t in formal talks, the people added.
AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that’s received U.S. approval for use with coronavirus patients.
Gilead is not currently interested in selling to or merging with another big pharmaceutical company, preferring instead to focus its deal strategy on partnerships and smaller acquisitions, the people said. A representative for Gilead declined to comment. A spokesman for AstraZeneca said the company doesn’t comment on “rumors or speculation.”
Coronavirus Treatment
The overtures show how the pharmaceutical industry landscape could shift at a time when drugmakers are racing to find effective treatments for Covid-19. If a deal goes ahead, it would surpass Bristol-Myers Squibb Co.’s $74 billion takeover of Celgene Corp. last year as the biggest-ever health-care acquisition, according to data compiled by Bloomberg. It would also rank among the 10 biggest M&A transactions of all time.
Shares of AstraZeneca have risen about 41% over the past 12 months, making it the best performer on a Bloomberg Intelligence index of major Western pharmaceutical companies. Shares of Gilead gained about 19% over the period.
The 10 Largest Health-Care and Pharma Deals -
Celgene / Bristol-Myers Squibb (2019) - 87.6
Warner-Lambert / Pfizer (1999) - 87.3
Allergan / AbbVie (2019) - 83.8
Shire / Takeda (2018) - 81
Aventis / Sanofi (2004) - 73.5
SmithKline Beecham / Glaxo (2000) - 72.5
Express Scripts / Cigna (2018) - 68.4
Aetna / CVS (2017) - 68.1
Allergan / Actavis (2014) - 65
Pharmacia / Pfizer (2002) - 64.3
Source: Bloomberg Deal values include debt
Gilead has attracted investor interest as its antiviral drug for Covid-19, remdesivir, worked its way through clinical trials in recent months. The stock is still more than a third lower than its 2015 highs. The Foster City, California-based company has seen a steady decline in sales in its hepatitis C franchise and is trying to reinvigorate its drug-development pipeline.
Remdesivir, which has an emergency use authorization from the U.S. Food and Drug Administration, has been shown in some early studies to shorten hospital stays for people with Covid-19. SVB Leerink recently forecast that sales of the drug may reach $7.7 billion in 2022.
Tamiflu Developer
Gilead has been dispensing early rounds of the drug for free, leading some investors to question how the company plans to make money from it in the future. Chief Executive Officer Daniel O’Day has said the company may spend $1 billion on the treatment this year alone.
AstraZeneca is helping to manufacture a Covid vaccine developed at the University of Oxford. The U.S. has pledged as much as $1.2 billion to support the efforts as part of Operation Warp Speed, a push to secure vaccines for America. The shot is expected to enter final-stage clinical trials in June.
Gilead was founded in 1987 by Michael Riordan, a doctor with a Harvard MBA who aimed to discover treatments for viral infections after a bout with dengue fever acquired in southeast Asia. The company’s best-known successes include Tamiflu, the influenza treatment it helped develop.
The company also makes Truvada, a medicine that can help prevent HIV, as well as drugs for liver disease and inflammation. Gilead employs about 12,000 people, according to its website.
AstraZeneca is no stranger to large-scale, politically sensitive M&A. In 2014 it fended off a $117 billion approach from Pfizer Inc., a deal that attracted attention from U.S. lawmakers as it would have allowed New York-based Pfizer to lower its tax bill by redomiciling in the U.K.
Deal Slump
Health-care dealmaking has been a rare bright spot as the global pandemic and resulting lockdowns have doused the market for mergers and acquisitions. Global M&A volumes are down about 45% this year, according to data compiled by Bloomberg, and announced deals have been falling apart at a steady pace.
Excluding minority investments, dealmaking in April and May barely topped $100 billion in total, the data show, the lowest two-month period in at least 22 years.
AstraZeneca CEO Pascal Soriot, a former executive at oncology specialist Roche Holding AG, has transformed the company since taking the helm nearly eight years ago. At the time, it was struggling with an aging stable of drugs and a shortage of innovation.
He’s championed the development of Lynparza, which was initially approved for ovarian cancer but has also proved useful for treating other forms of the disease. AstraZeneca has since overtaken U.K. rival GlaxoSmithKline Plc in market value.
Last year, AstraZeneca sealed its biggest transaction in more than a decade, agreeing to pay as much as $6.9 billion to buy into a promising breast cancer treatment developed by Japanese drugmaker Daiichi Sankyo Co. The U.K. company reached a deal this month with Accent Therapeutics Inc. to potentially spend more than $1.1 billion collaborating on novel oncology therapies.
AstraZeneca shares have also been boosted by positive data from trials of its blockbuster lung cancer drug Tagrisso.
<<<
AVCT just merged with Computex Technology Solutions. $85 million in revenue in 2019. Increasing revenue yoy. This should be trading at $400 million market cap. Instead trading at $35 million market cap.
>>> Aqua America / Essential Utilities - Post-Merger Aqua America: Great Company, High Price
Forbes
by Roger Conrad
1-20-20
https://www.forbes.com/sites/greatspeculations/2020/01/20/post-merger-aqua-america-great-company-high-price/#7aafd95249aa
I’ve personally owned Aqua America (WTR)—which on February 3 will rename itself Essential Utilities (WTRG)—since it was Philadelphia Suburban. And thanks to the wealth-compounding power of dividend reinvestment, my Aqua shares are worth almost 14 times what I initially put in.
I’ve also consistently recommended Aqua in my advisories. And I’ve had the privilege of meeting with current CEO Chris Franklin, as well as several times with the architect of the company’s three-decades-old growth through acquisitions strategy, Nicholas DeBenedictis.
Nick was one of the first employees of the Environmental Protection Agency in 1972, and later served in the cabinet of former Pennsylvania Governor Richard Thornburg. From those experiences, he perceived the opportunity for water utilities like Philadelphia Suburban to profitably consolidate their wildly fragmented sector.
I interviewed Nick for my 2002 book "Power Hungry: Strategic Investing in Telecommunications, Utilities & Other Essential Services." His comments then have proven prescient, both for Aqua and the US water sector overall. In fact, his insights are very much at the root of the success I’ve had investing in water utilities the past two decades.
The focus of my March 10, 2016 article "Water World: An Interview with Chris Franklin, CEO of Aqua America" was the latest phase of the company’s M&A strategy: Acquiring municipally owned water and wastewater distribution systems.
Franklin’s comments then have since proven equally on the mark, though developments have likely taken longer to unfold than he anticipated. The company’s proposed DELCORA acquisition would be the largest water and wastewater deal in state history, if the Pennsylvania Public Utility Commission approves as expected.
Today, Aqua serves roughly 3 million water customers in Pennsylvania, Ohio, North Carolina, Illinois, Texas, New Jersey, Indiana and Virginia. In the next few days, however, it will complete its most transforming deal yet: The all-cash $4.28 billion purchase of natural gas distribution utility Peoples Gas, which serves roughly 740,000 homes and businesses in western Pennsylvania, West Virginia and Kentucky.
I first discussed the Peoples acquisition when I recommended Aqua as a Conservative focus stock in the November 2018 issue of Conrad’s Utility Investor. Since then, shares have appreciated by more than 50 percent. And I’m convinced as ever that my initial bullish observations will prove accurate.
The purchase will be immediately accretive to Aqua’s earnings, adding a gas distribution franchise with annual rate base growth of 8 to 10 percent for the next few years. The merger did take somewhat longer to close than management’s initial projection of "mid-2019." But at the end of the day, the deal closed without significant new conditions and after Peoples secured an amicable rate deal.
Aqua also attracted a $750 million equity investment from the Canada Pension Plan Investment Board. That reduced prospective deal financing costs.
So has the sharp reduction in Aqua’s cost of debt capital over the past year. That point is best demonstrated by the drop in yield to maturity for its bonds of May 2049, from roughly 4.3 percent when they were issued in late April 2019 to just 3.5 percent this past week.
Adding Peoples should also open up a new range of acquisition targets for Aqua as it adds new geography. And the combined company will also benefit from the synergies of operating gas distribution and water utilities in the same area. As Essential Utilities, it will start out with nearly 80 percent of rate base in Pennsylvania, where management has built one of the most constructive regulatory relationships of any utility in the country.
The history of M&A is packed with examples of acquiring companies losing their way after entering a new business. And that includes plenty of utilities and essential service companies.
Regulated natural gas and water utility convergence, however, has a successful track record. In fact, it’s likely that buying Peoples will accelerate Aqua’s already upper single digit underlying earnings growth rate, possibly by a couple percentage points. And the merger increases the combined company’s appeal as a potential takeover target as well.
I’ve mentioned Exelon Corp (EXC) before as a likely eventual suitor for Aqua. Early in the previous decade, that company shifted its strategy to focusing on growing its regulated electricity transmission and distribution rate base rather than adding nuclear generating capacity, acquiring the former Pepco Holdings in March 2016.
Buying Aqua, which has less than one-quarter its market capitalization, would greatly accelerate that goal. And there’s even a potential human link, as former CEO DeBenedictis was once an employee and board member of Exelon.
So what’s not to like about a company that just accelerated its long-term growth rate and reduced business risk at a low cost, and is a perpetual takeover candidate? Two words: Extreme valuation.
Following regulatory approval of the Peoples merger, Aqua shares surged to a price more than 35 times expected 2020 earnings per share. That’s the highest multiple in the company’s history and compares to a likely 8 to 10 percent post-merger growth rate.
Today, there are a third fewer publicly traded water utilities than when Mr. DeBenedictis compared his sector to collector cars in my book Power Hungry. And Aqua’s current valuation is very much in line with the rest of the group, including American Water Works (NYSE: AWK) at 34.2 times expected 2020 earnings. In fact, it’s cheap compared to neighboring York Water (NSDQ: YORW) selling at 40 times.
Scarcity plus little real operating risk is why I plan to continue reinvesting my Aqua/Essential dividends, rather than selling. But it’s very difficult to see shares making real headway any time soon from these levels. Neither is the stock attractive for income now yielding just 1.85 percent.
That’s why my advice for anyone wanting to buy into this otherwise great company is to be patient for a better price. Note changing the name from Aqua to Essential Utilities is a not a taxable event and won’t change either ownership or dividends paid.
<<<
>>> Buy These 3 Former United Technologies Stocks. They’re Ready to Fly.
Barron's
By Andrew Bary
April 17, 2020
https://www.barrons.com/articles/the-bull-case-for-3-new-stocks-raytheon-technologies-otis-and-carrier-51587162109
Three industrial companies have made their debut at possibly the worst time for any business.
Yet the three— Raytheon Technologies (ticker: RTX), Otis Worldwide (OTIS), and Carrier Global (CARR)—all look appealing, despite a downturn that will sap this year’s results. Their emergence follows the completion earlier this month of the merger between Raytheon and United Technologies.
Raytheon Technologies is by far the largest of the three, with a market value of $95 billion. It consists of United Technologies’ commercial aircraft operations, including the Pratt & Whitney engine business; a defense unit, and all of Raytheon, one of the leading defense contractors. Its shares, at a recent $65, trade for 17 times projected 2020 earnings of $3.82 a share.
The bull case for Raytheon Technologies is that its relatively stable defense business—accounting for about 65% of projected revenues in 2020 and 2021—should anchor the company until a rebound in the hard-hit aerospace units comes in 2022.
The company “ran into the buzz saw of the biggest downturn in aerospace history,” says Carter Copeland, an analyst with Melius Research. “You have to believe that people will hop on planes again and that the industry will need new jet engines and that planes will consume spare parts.”
Calling Raytheon Technologies a “lower risk” way to invest in aerospace, compared with Boeing (BA) and Airbus (AIR. France), he has a Buy rating and a $80 price target on the stock.
During 2019, United Technologies and Raytheon projected $8 billion to $9 billion in free cash flow in 2021 for the new Raytheon Technologies. But $6 billion now looks more likely, with $7 billion to $8 billion—about $5 a share—possible in 2022. That is against $7.5 billion last year and a projected $4.5 billion for 2020.
“Not exactly the way we had expected to start this great company, but we’ll get through it,” Greg Hayes, Raytheon Technologies CEO (and former boss of United Technologies), told Fox Business in early April. The company, he said, would rely on its defense businesses, with their $70 billion contract backlog, for growth in the near term.
One risk for Pratt & Whitney is that accelerated retirement of older jets from airline fleets will hurt its lucrative spare parts business. But it should benefit in the coming years from an upturn in profits on its new jet engine (called the geared turbofan) for narrow-body Airbus planes.
3 Stocks From 2
Deal-making by the former United Technologies has now led to the creation of three industrial stocks.
Company / Ticker Recent Price Market Value (bil) 2020E EPS 2021E EPS 2020E P/E 2021E P/E Net Debt (bil)
Raytheon Technologies / RTX $62.45 $94.7 $3.82 $4.69 16.4 13.3 $22.0
Otis Worldwide / OTIS 45.62 19.8 1.94 2.20 23.5 20.8 4.8
Carrier Global / CARR 12.89 11.2 1.40 1.70 9.2 7.6 10.0
E=Estimate
In the merger, Raytheon holders received 2.335 shares of Raytheon Technologies for each of their shares, while United Technologies holders received one share of Raytheon Technologies, one of Carrier, and a half-share of Otis for each United Technologies share.
Otis recently traded at $45, and has the highest valuation among the three, at 23 times projected 2020 earnings of $1.94 a share. This reflects Otis’ position as one of the five global leaders in elevators and the only elevator pure play in the U.S. stock market.
JPMorgan analyst Stephen Tusa began coverage of Otis with an Overweight rating and a $53 price target.
“It’s a strong franchise in an attractive industry and better earnings visibility in the downturn,” relative to others in the building-services industry, Tusa says. Elevators, he noted in a recent report, “are like the aircraft engine of the building, a technical, mission-critical piece of equipment for which failure is not an option.”
Otis notes that about a third of the 16 million elevators around the world are at least 20 years old. About 80% of its earnings come from stable services revenue. The company’s medium-term goal is high single-digit annual growth in earnings per share. Earnings may decline 14% this year, to $1.94 a share, before rebounding to $2.20 in 2021.
With a high tax rate of 33% depressing earnings, Tusa prefers to value Otis based on enterprise value (equity market value, plus net debt) divided by earnings before interest, taxes, depreciation, and amortization, or Ebitda, which is more reasonable at around 12.5, based on this year’s projected results, and represents a discount to rivals Kone (KNEBV.Finland) and Schindler Holding (SCHN. Switzerland).
Carrier is a top maker of air-conditioning and heating systems. It is the deep-value stock of the three, trading at $13, or about 10 times this year’s projected earnings per share. A big knock against Carrier is its heavy net debt of $10 billion, or five times estimated 2020 pretax cash flow (Ebitda). Most companies like to keep the ratio of debt to Ebitda to three times or less.
Wolfe Research analyst Nigel Coe began coverage of Carrier with an Outperform rating and a $26 stock price target. He sees “substantial opportunities to improve margins and pay down debt,” according to a note.
Coe projects $1.2 billion of free cash flow this year, rising to $2 billion by 2022 or 2023. Revenue this year is expected to be down 15%, to $16 billion, with reported earnings off by a third. Carrier, he wrote, is “best viewed as a deleveraging and restructuring story—perhaps not the jazziest equity story, but one that we think can deliver significant upside, if executed well.”
Carrier may set a dividend that could be 4%, according to Barclays analyst Julian Mitchell. Raytheon and Otis are each expected to yield about 2%.
In sum, Raytheon Technologies is a mix of a stable defense unit and a recovering aerospace division. Otis offers a pure play on an attractive global oligopoly, while Carrier is an industry leader with a depressed price.
<<<
DEEL $025 WENT UP PINK CURRENT BY OTC MARKETS YESTERDAY.... J. ARCARO NEW CEO! REVERSE MERGER AROUND THE CORNER? 28M ULTRA LOW FLOATER. ARCARO'S LAST R/M WAS NUGS FROM 000 TO $7. MUST WATCH FOR NEXT DAYS/WEEK
https://www.otcmarkets.com/stock/DEEL/disclosure
*** DEEL 0116 REINSTATED 08/09/2019 08/12/2019 + J. Acaro Shell since 2 weeks!! R/M next? Boooommmmmmmmmmmmmm coming next SOLI type mover imo
20190091283 Certificate of Reinstatement
https://esos.nv.gov/EntitySearch/BusinessFilingHistroyOnline
Link of filing https://www.clarkcountycourts.us/Portal/Case/CaseDetail?eid=4xB2x1bzJKNVgM6xsjnR2Q2&tabIndex=3
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |